BioTOP-Report
2012
Biotechnology in Berlin-Brandenburg
BioTOPics 44 | May 2012 BioTOP-Report
Content
Editorial
Excellence in Life Sciences and Healthcare
3
Industry
Biotech Industry Continues to Grow
4
Biotech Parks
The BioCampus Network Berlin-Brandenburg
18
Life Sciences
Excellent Research in Berlin-Brandenburg
24
Theranostics
A New Approach in Individualized Healthcare for the Future
28
Health-IT
New Opportunities for Biotechnology on the Interface between Life Sciences and IT
30
Biomaterials
Biotechnologically Improved Biomaterials from Berlin and Brandenburg
32
Bioeconomy
Towards the Age of the Bioeconomy
42
Global Business
The Role of Berlin-Brandenburg in the European Context
44
Education
Knowledge-Based Leadership
46
Addresses
49
Publisher: TSB Innovationsagentur Berlin GmbH · Division Life Sciences/Healthcare · BioTOP Berlin-Brandenburg Fasanenstraße 85 · 10623 Berlin · Germany · Phone +49 30 318622-0 · Fax +49 30 318622-22 · biotop@biotop.de · www.biotop.de Editor: Yvonne Küchler Design & Production: supiran.de Translation: Textbüro Reul GmbH · Frankfurt Photos/Figures: BioTOP or Authors and: Titel: Jankaliciak* (DNA-molecule) Kirsty Pargeter* (DNA), Andreiadis* (Molecule background), Dzombie* (Hand), Christoph Buckstegen (Sony Center), Andrey Armyagov* (Test tubes) Page 5: Lightpoet*, Maximus117; Page 9: Martin Joppen (Portrait Maas) Page 10: Ioana Davies*; Page 11: Bernd Blumrich (Portrait Siodla); Page 22: Vanillla*; Page 24: Silke Oßwald, FMP (Portrait Haucke); Page 25: MDC/David Ausserhofer (Portrait Rosenthal), Helmholtz/Dawin Meckel (Portrait Mlynek) Page 26: Chaoss*, Raduhuc*; Page 31: Frank Nuernberger (Portrait Tosun) Page 44: Moth*; Page 48: TSB/Uwe Steinert [*dreamstime.com]
BioTOPics 44 | May 2012 BioTOP-Report
Editorial
Excellence in Life Sciences and Healthcare
Over the past 20 years, the biotechnology industry in Berlin-Brandenburg has developed into an innovation driver which also influences many other sectors. Both in research and industry, we have seen continuous growth in the number of institutions and companies engaged in biotechnology. This growth is driven primarily by excellent research. The region’s unique density of prestigious science and research facilities forms an ideal breeding ground for the foundation and location of research-oriented health sector companies. Internationally, Berlin-Brandenburg now counts as one of the world’s leading healthcare and life science locations.
Dr. Kai Bindseil Director BioTOP Berlin-Brandenburg Cluster Manager HealthCapital bindseil@biotop.de www.biotop.de
More than 200 biotechnology and 30 pharmaceutical companies are located in the German Capital Region. They include global corporations like Bayer HealthCare, Bausch & Lomb, B. Braun Melsungen, Berlin-Chemie, Pfizer, Sanofi and Nycomed Takeda. Along with the sector’s many small and mid-sized companies, they benefit from close cooperation, both with science and with more than 130 hospitals – among them, above all, one of Europe’s largest university hospitals: Charité – Universitätsmedizin Berlin.
Based on its excellence in interdisciplinary and translational cooperation, the Cluster HealthCapital Berlin Brandenburg is generating innovations which are to benefit patients as soon as possible. Close networking of all players in the region is essential to accelerate the translation of the newest research findings into innovative products. As part of the joint innovation strategy of the states of Berlin and Brandenburg (innoBB), this task was assigned to the cluster management organisation HealthCapital. BioTOP forms part of this cluster management, and we are pleased to present the most important developments in the life sciences, pharmaceuticals and biotechnology to you in this BioTOP-Report 2012 in the new layout of the Cluster HealthCapital. We hope you enjoy reading our report and look forward to continuing good cooperation with you.
The new capabilities of IT-based technologies open up entirely new potentials for biotechnology and healthcare in the direction of increasingly personalised diagnostics and therapy. In this regard, too, the German Capital Region is a founder Mecca of the IT industry and boasts major companies and institutions like SAP, Siemens and the Hasso Plattner Institute (HPI) in Potsdam. Dr. Kai Bindseil
3
BioTOPics 44 | May 2012 BioTOP-Report
Industry
Biotech Industry Continues to Grow
The Berlin-Brandenburg biotech industry has continued to develop positively in 2011. As in previous years, the number of employees grew by 4 %. Compared to the average growth rate of 3.5 % of the last years, that is a good result and a sign of the dynamism in the Berlin-Brandenburg region. Currently 215 companies employ 4,068 people here.
Business development in 2011 Once again in 2011, BioTOP carried out a survey of regional companies to learn about current developments and gain a comprehensive overview of the business landscape. In 2011, the number of companies increased by 17 newly registered businesses. They include five new start-ups, six companies that began their business operations in 2011 and six that were newly listed. Two companies ceased operations.
customer-specific SNP analysis and focusing on the development of diagnostic DNA markers for complex attributes. Another is TissUse GmbH, which was founded by TU Berlin and is a product of the GO-Bio competition sponsored by the German Federal Ministry of Education and Research (BMBF). The company has developed the following innovation: Using a multi-organ bioreactor in chip format, substances can be tested on humans even before exposition, thereby enabling the prediction of consumerrelevant reactions.
The new companies are smaller units with a strong focus on services and product developments that are close to the market. One example – financed by the High-Tech Gründerfonds – is the OakLabs GmbH, providing services and products in the field of
Overall, there has been little change in the size of companies in recent years. 62 % of all companies recorded are small businesses with fewer than ten employees. However, those companies employ less than 16 % of the sector’s workforce, while 32 %
JANUARY 2011
inclusion criteria for the MOLOGEN AG clinical study of the colorectal cancer medicine MGN1703 are broadened. This creates the opportunity to obtain the expected market approval for the drug independently of a specified first-line therapy ++++ Caprotec bioanalytics increases series B financing in second closing to 5 million Euros
RNL Bio (Korea) acquires the Berlin stem cell company Pharmicell Europe ++++ QIAGEN to acquire stake in Alacris, gaining access to biomarker pipeline for use in personalized healthcare assays ++++ GILUPI GmbH: VC funding in the amount of Euro 3.6 million
FEBRUARY 2011
JUNE 2011
MOLOGEN AG: Euro 10 Mio capital increase ++++ The European Commission awards the newly created “Region of Excellence” label to Brandenburg
Silence Therapeutics` Atu027 demonstrates promising anti-tumour activity in Phase I study presented at ASCO ++++ BIOTECON Diagnostics completes development of a rapid test for EHEC (enterohemorrhagic E. coli) to combat the epidemic which also provides specific proof of the circulating EHEC strain O104:H4 ++++ The start-up company Spreelabs of Freie Universität Berlin receives award in the business plan competition Science4Life Venture Cup 2011 for its temperature reference plate also named “DNA Thermometer”, which has been registered for patent.
MARCH 2011 Algenol announces acquisition of Cyano Biofuels GmbH ++++ Revotar Biopharmaceuticals meets primary endpoint in Phase II COPD study with inhaled Bimosiamose
APRIL 2011
JULY 2011
Co.don AG: exclusive agreement with Novomedics GmbH to distribute its cellbased therapy chondrosphere® for Switzerland ++++ Glycotope Biotechnology expands GMP production facility to 11 kg antibody per year and starts phase I clinical trial of FSH-GEX for the treatment of anovulatory infertility
Metanomics Health officially launches its Energy Metabolite Platform, a unique target platform based on metabolite profiling of the energy status of a biological system
MAY 2011
AUGUST 2011
Lonza and ORGANOBALANCE enter global license agreement to develop and market unique probiotic (Lactobacillus anti-H. pylori) ++++ The patient
ProBioGen licences its innovative GlymaxX® technology to Boehringer Ingelheim ++++ co.don AG cultivates cartilage cell transplants for the Asklepios
4
BioTOPics 44 | May 2012 Industry BioTOP-Report
work in companies with 11-50 employees. More than 52 % of all employees in the region’s biotech industry work for the 19 companies that have more than 50 employees. The thematic focus also remained unchanged in recent years. The main remains biomedicine, and here diagnostics.
Deals and product developments The year 2011 saw a range of new cooperation agreements and important milestones in product development. Here are a few selected examples from the wide spectrum of activities: ProBioGen AG, a specialist in developing production cell lines, process engineering and the GMP production of biopharmaceutical active agents, has been very active. The company closed several license agreements to use their cell lines, including a nonexclusive license agreement with Boehringer Ingelheim to use ProBioGen’s innovative glyco-engineering technology "GlymaxX" Boehringer Ingelheim will use the technology in biopharmaceutical contract development and production. ORGANOBALANCE GmbH signed a worldwide exclusive license agreement with Lonza under which the licensee develops, produces and markets a probiotic lactobacillus strain. The probiotic strain developed by ORGANOBALANCE acts against Helicobacter pylori (H. pylori). The license provides Lonza with the basis for access to the probiotic market.
Group, Germany’s largest private hospital group ++++ The first evaluation data from the clinical study of MGN1601 by MOLOGEN AG in kidney cancer therapy are far more encouraging than expected
SEPTEMBER 2011 The colorectal cancer test Epi proColon® 2.0 developed by Epigenomics detects 95 % of cancer cases in a clinical trial ++++ Glycotope enrols first patients in phase I trial with TrasGEX (TM), a glycooptimized HER2 biobetter antibody ++++ ATLAS Biolabs joins the bioinformatics project NGSgoesHPC of the German Federal Ministry of Education and Research (BMBF)
OCTOBER 2011
DECEMBER 2011 SCIENION founds the US subsidiary SCIENION US, Inc. ++++ The new method developed by the company Caprotec called Capture Compound Mass Spectrometry is used to research new anti-cancer agents in cooperation with the Leibniz-Institute for Molecular Pharmacology (FMP) ++++ NOXXON completes Phase I trial for the SDF-1 inhibitor NOX-A12
JANUARY 2012 ORGANOBALANCE signs licence agreement with Sanofi Pasteur for access to a modified yeast strain for vaccine applications ++++ EPO starts strategic cooperation with vivoPharm to enhance its market position in the US.
FEBRUARY 2012
Humedics successfully closes its first VC funding contract with Charité Biomedical Fund, VC-Fonds Technologie, KfW, the German high-tech start-up fund HTGF und Ventegis Capital AG ++++ Epigenomics announces market launch of Epi proColon® 2.0 CE in Europe ++++ ProBioGen and Inhibrx sign licence deal on GlymaxX® ADCC technology for therapeutic antibody development
The Epi proLung® BL assay by Epigenomics demonstrates good performance as a confirmation test for patients with suspected lung cancer ++++ Construction starts on Europe’s largest hospital laboratory in Berlin-Wedding: Groundbreaking ceremony for the operations facility of Labor Berlin – Charité Vivantes GmbH
NOVEMBER 2011
MARCH 2012
MOLOGEN AG achieves the targets of its kidney cancer study with MGN1601 ahead of schedule ++++ co.don AG receives the entrepreneur award of the Eastern German Savings Bank Federation (OSV), one of the most prestigious distinctions awarded in Germany’s eastern federal states
ProBioGen's licenses its AGE1.CR® cell line for viral vaccine production to Ceva ++++ SCIENION introduces sciREADER CL for colorimetric detection of multiplex assays
5
BioTOPics 44 | May 2012 BioTOP-Report Industry
EPO Berlin-Buch GmbH has closed a cooperation agreement with vivoPharm, an Australian/American company. vivoPharm also focuses on preclinical pharmacological research and will make the primary tumour models developed by EPO more intensively available to cancer research facilities in the USA. For the first time, EPO technologies are therefore giving biotechnology and pharmaceutics companies in the USA the opportunity to test the cancer medicines they are developing in models that are close to clinical practice and to seek and validate predictive (bio-) markers for their efficacy. In the field of regenerative medicine, co.don AG has signed a framework agreement with Germany’s largest association of clinics, the Asklepios Group. It enables Asklepios Clinics throughout
Germany to treat patients with the cell-based biological medicine ARTROCELL 3D®/co.don chondrosphere®. The product is used for regenerative treatment of cartilage damage, e.g. of the knee, and is an ideal extension of the therapies offered by the Asklepios Hospitals. KNAUER GmbH announced a license and cooperation agreement with ChromaCon AG, under which ChromaCon grants KNAUER a semi-exclusive license for world-wide marketing, distribution and after-sales services of the Contichrom™ lab-scale preparative chromatography unit for use in discovery, process development and small scale production. In an internationalisation measure, Scienion AG founded an American subsidiary in Princeton to develop a base in this important key market and meet the growing
Number of Employees According to Company Size
2.200 2117
2.100 2.000 1.900 1.800 1.700 1.600 1.500
1.300
1306
Number of employees
1.400
1.200 1.100 1.000 900 800 700 645
600 500 400 300 200 100
0 02 03 04 05 06 07 08 09 10 11 134 companies 1-10 employees
02 03 04 05 06 07 08 09 10 11 62 companies 11-50 employees
02 03 04 05 06 07 08 09 10 11 19 companies > 51 employees
In comparison to the previous year, the average number of employees per company increased by 4,5 % in the 1-10 category and decreased by 5 % in the 11-50 category. The average number of employees in the category > 50 employees increased by 10%. (Source: Own survey, BioTOP database, 215 companies questioned, February 2012)
6
BioTOPics 44 | May 2012 Industry BioTOP-Report
demand for sciFLEXARRAYER dispenser machines and microarrays manufactured by Scienion.
Companies working on the development of innovative medicines achieved important milestones in 2011:
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announced that it has entered into an agreement with Mirna Therapeutics Inc., a biopharmaceutical company pioneering microRNA-based therapeutics for cancer, to assess the delivery capabilities of Silence’s proprietary AtuPLEX™ and DBTC delivery systems for Mirna’s novel microRNAs. Under the terms of the agreement, Mirna will provide Silence with specific miRNA sequences, which Silence will formulate with its AtuPLEX™ and DBTC delivery systems in order to develop multiple candidate drugs.
MOLOGEN AG, which specialises in the research and development of innovative medicines based on DNA structures, fully achieved the primary study targets ahead of schedule in the Phase I/II clinical study on their kidney cancer medicine MGN1601, which has shown a significant survival benefit for patients. At the same time, the approval-relevant Phase II/III study on the intestinal cancer medicine MGN1703 is also progressing. It is the most developed product in the MOLOGEN AG pipeline. The DNA immune modulator MGN1703 will now be clinically tested for treating advanced lung cancer.
You need commitment, focus and passion to find new ways to fight the diseases of this world: innovation is at the heart of it. Innovation for better health. Our commitment is to bring to patients around the world quality medicines for use in diag nosing, combating and preventing disease. Every day we work against time, researching new pathways, new molecules, new technologies – complementing our own capabilities with exper tise of innovative partners from science and industry.
The success of this work is evidenced in new medicines for areas with significant unmet medical need such as oncology, cardiovascular and blood diseases, as well as gynecology and ophthalmology. Our aim is a better quality of life for all.
www.bayerhealthcare.com www.bayerpharma.com
29407011_BHC_Imageanzeige_210x135mm_RZ.indd 1
29.08.11 12:33
BioTOPics 44 | May 2012 BioTOP-Report Industry
The product portfolio of Glycotope, a global leader in optimizing the glycosylation of biopharmaceuticals, now encompasses a variety of antibodies and non-antibody biologics, 4 of which are currently in the clinical stage. This pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX™) and significantly improved versions of antibodies as well as other already marketed therapeutic proteins, so called Biobetters. NOXXON Pharma, a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers has a diversified portfolio of clinical stage Spiegelmer therapeutics. For instance, Spiegelmer® NOX-E36 targets the pro-inflammatory chemokine MCP-1 (CCL2) which is implicated in diabetic complications including nephropathy. NOX-E36 is currently completing a Phase Ib study in healthy subjects and diabetics, and a Phase IIa diabetic nephropathy study is currently
Employees in Biotech SMEs
09
4.068
3.727
08
3.904
3.700
04
3.427
03
3.213
3.003
2.942
3.007
3000
3.590
3500
2500 Number of employees
In recent years there were a number of acquisitions, such as the take-over of the diagnostics company B.R.A.H.M.S by Thermo Fisher Scientific, but 2011 was exceptionally quiet in this respect and no significant take-overs were recorded. Looking back, one can conclude that the more than 15 take-overs in the past few years have on the whole strengthened the affected companies, which have strategically benefited from them. Overall, the regional industry is in very good shape and developing with great dynamism. In view of the changing situation in the pharmaceuticals industry, which is characterised by increased outsourcing and personalised therapeutic concepts, the biotech companies in Berlin-Brandenburg are well placed for the challenges of the future.
Pharmaceutical Industry in the Capital Region
4000
2000
1500
1000
500
0 02
05
06
07
10
11
Employment rose to 4.068 in 2011. The number of companies went up to 215, reflecting the arrival of 17 companies and 2 departures. (Source: Internal survey, BioTOP database, 215 companies questioned, February 2012)
8
in preparation. Spiegelmer® NOX-A12 targets SDF-1 (CXCL12), a chemokine mediator of tumour invasion, metastasis and resistance to chemotherapy, and has completed Phase I and Phase IIa studies in two haematological oncology indications have recently been started.
Major global corporations are located in the German Capital Region: Bayer Pharma AG, Berlin-Chemie AG, Pfizer Deutschland GmbH and Sanofi-Aventis Deutschland GmbH. They are joined by more than 20 mid-sized pharmaceutical companies, including several international market leaders. For example: Bausch + Lomb – Dr. Mann, the world’s leading manufacturer of ophthalmic medicines. In 2011 sales revenues of more than 5 billion Euros were generated by the pharmaceutical products of 24 Berlin-based companies. The German capital’s pharmaceutical industry is growing strongly and creating modern jobs. It already employs some 10,000 people in the region, thereby providing about one in ten of all jobs in the city’s manufacturing sector. The Japanese pharmaceutical corporation Takeda is the most recent arrival, having relocated its German distribution units from Aachen and Konstanz to Berlin. In the Capital Region, innovation meets tradition – this is the formula that underpins the sustained success of the region's pharmaceutical industry. The tradition has a long history. Since the middle of the 19th century, manufacturing companies have produced medicinal products here, and some of those erstwhile
BioTOPics 44 | May 2012 Industry BioTOP-Report
pioneers now belong to the world’s leading pharmaceutical manufacturers. They started modern research and production during the past century and went on to shape the development of medicine. Two examples: kk In 1930, the world‘s first injectable kidney contrast agent was developed in Berlin. The product revolutionized the examination of kidney diseases. kk In the 1960ies, Europe’s first contraceptive pill was developed in Berlin. This successful tradition ensures that the industry identifies strongly with Berlin as a pharmaceuticals location. The industry’s current research focus areas in the German capital include cardiology and oncology (e.g. Bayer Healthcare), inflammatory diseases and pain therapy (Berlin Chemie). The region’s large number of research facilities, SMEs and pharmaceutical companies provides a unique platform for a wide range of cooperation alliances too. The pharmaceuticals corporation Sanofi, for example, is embarking on a major alliance project with Charité – Universitätsmedizin Berlin. Shared ideas and themes, joint research and working together day by day form the foundation for this cooperation. The partners have just opened
Dr. Dieter Hübl Chairman of the North-Eastern Regional Association of the German Chemical Industry Association (VCI)
Berlin is the center of the German pharmaceuticals industry, right in the heart of a high-performing region. Pharmaceutical companies have access to many cooperation partners here because the German capital is home to internationally renowned hospitals, research institutes and outstanding universities. The region is a global leader in biotechnology, and its pharmaceuticals industry is developing pioneering innovations. As core sectors, they are also stimulating broader growth in the regional economy.
Prof. Dr. Jochen Maas Managing Director Research & Development Sanofi-Aventis Deutschland GmbH
Cooperation with external partners is increasingly important for Sanofi, as indicated by our joint project with the Charité in Berlin. We are cooperating in the fields of stroke, inflammatory immunity disorders and diabetes.
their first joint laboratory near the Charité in Berlin-Mitte, where their scientists are conducting stroke research. This is one of the five themes the partners agreed on after 25 conferences. Other fields in which Charité and Sanofi want to cooperate in future are rheumatism, diabetes, rheumatoid arthritis and regenerative medicine. The project OncoTrack is another example for the region’s cooperation potentials. It has brought together an international consortium of more than 60 representatives from science and industry and has launched one of Europe’s biggest cooperative research projects to develop new methods for the identification of novel colorectal cancer markers. Bayer HealthCare Pharmaceuticals and the Max Planck Institute for Molecular Genetics (MPIMG) are coordinating the consortium’s activities. The unique OncoTrack project on „Methods for systematic next generation oncology biomarker development“ is currently scheduled for a term of five years and is bringing outstanding scientists from a range of disciplines and academic institutions across Europe together with representatives from the pharmaceutical sector. The major pharmaceutical industry associations are also present in Berlin as important actors who represent the interests of the pharmaceuticals and biotechnology sector at the political level. The German Association of Research-Based Pharmaceutical Companies (vfa) and vfa bio, the German Federal Pharmaceutical Industry Association (BPI), the German Chemical Industry Association (VCI) with its regional eastern German association and BioDeutschland are all headquartered in the German capital. This provides potent synergies for promoting shared objectives. For example, alongside many other cooperative projects, BioTOP 9
BioTOPics 44 | May 2012 BioTOP-Report Industry
organised the acclaimed symposium “Personalised Medicine: Benefits for Patients and Society” in cooperation with vfa bio, the biotechnology group of the vfa. BioTOP and its partners in the cluster management organisation ZukunftsAgentur Brandenburg (ZAB) and at Berlin Partner support international pharmaceuticals companies looking for potential cooperation partners in science and in biotech SMEs. In recent months, for example, we welcomed international delegations from Genzyme, Pfizer and Novartis and organised structured partnering with regional scientists and companies.
Financing situation Some capital-intensive companies are still using money from funding rounds in previous years. Most companies provide funds for themselves as part of organic growth, naturally also due to the difficulty of accessing external financial resources. Public support therefore remains an extremely important factor for developing new products, since it is still the case that only few companies have access to VC funding. According to a study by Fleischhauer, Hoyer & Partner, a panel of 36 leading VC investors, investment in Germany fell from Euro 505 million in 2010 to Euro 445 million in 2011 (panelists only). That represents a 14 % drop, but is nevertheless a 24 % increase compared to 2009. Most of the capital was invested in biotechnology (Euro 70 million) and medical technology (Euro 66 million). The regional distribution of all investment shows Berlin-Brandenburg in third place behind Bavaria and North RhineWestphalia.
Market Segments of Companies
190
83%
180 170 160 150 140 130 Number of companies
120 110 100 90 80 70 60 50
19%
40 30
13%
20 10 0
27 02 03 04 05 06 07 08 09 10 11 Agriculture/Food
40 02 03 04 05 06 07 08 09 10 11 White Biotechnology /Environmental Biotechnology
178 02 03 04 05 06 07 08 09 10 11 Biomedicine
Most companies focus on biomedicine. A total of 83 % of companies, focus primarily on development in the areas of new diagnostics, drug development and associated services or technologies. 13 % of the companies are active in the agriculture/food sector, white biotechnology/environmental biotechnology amounts to 19 % of all entries. (Source: Internal survey, BioTOP database, responses from 215 companies, multiple entries, February 2012)
10
BioTOPics 44 | May 2012 Industry BioTOP-Report
Following this general trend over Euro 40 million were invested in regional companies in 2011. That is half the amount of the previous year. However, capital requirements were not so high since companies had acquired sufficient funding in 2010. So a higher result is expected again in the future. IBB Beteiligungsgesellschaft (IBB Bet) stands out as the region’s highest investor, with funding for companies such as Caprotec, OctreoPharm Sciences, Humedics and NDI. The newly founded Charité Biomedical Fund, which is managed by Peppermint Venture Partners, made its first investment in 2011 by funding Humedics. Vilma Siodla COO and CSO co.don AG
co.don AG has been based in Teltow since 1993. The decision for this location was a good one because Teltow offers a perfect environment for our company. The many universities in the region ensure that we find many qualified professionals here along with a modern infrastructure. The State of Brandenburg supports us with its funding programmes. For example, Brandenburger Investitionsbank approved funding in the amount of 2.5 million Euros for regenerative joint therapy in September 2010, of which 75% were provided by the European Regional Development Fund (EFDF) and 25% from budget funds of the State of Brandenburg. co.don AG used these funds in part to commission a clinical study for scientific evaluation of the already tried and tested use of cell transplants in joint defect therapy.
In addition to private investment, public funds are provided by the federal states for fixed-asset investment and new product developments worth Euro 42 million. The leverage effect generated a further Euro 45 million in private investment. The federal government and the EU provide additional double-figure million Euro funding. Public-sector institutions consequently remain extremely important partners for many small businesses. The good overall result nevertheless continues to be marked by limited finances on the capital market. Many companies have
Ute Mercker Vice President/Head of Life Science IBB Beteiligungsgesellschaft mbH
IBB Beteiligungsgesellschaft and its funds have been investing in innovative biotech and medicine start-ups in Berlin for 15 years now. The German capital stands out due to its large range of universities, academies and research facilities. This creates tremendous potential for innovative start-ups, and our investment strategy aims to develop them into thriving companies. We invested in Noxxon Pharma AG, Jerini AG and Scienion AG shortly after their spin-off from the university. In the meantime, they have established their products successfully on the market. In 2011 we successfully invested in four other start-up companies. Octreopharm Science GmbH and Humedics GmbH will use the invested capital to implement clinical trials. Due to our regional focus, we can support our companies flexibly and swiftly with our extensive experience during the start-up phase.
detached themselves from the capital market due to the lean period that has lasted for years, and have adapted their business models to make them as independent as possible. So it is all the more encouraging that the subject of venture capital funding has once again become an important policy agenda, with the aim of removing key hindrances and improving framework conditions. In this context, one positive sign is that High-Tech Gründerfonds (HTGF), the leading investor in innovative start-ups, has created a new fund worth more than Euro 280 million, thereby continuing to be one of the few investors that play a strong, consolidating role in the start-up sector. However, HTGF cannot finance the full potential for new company start-ups and can only provide selective investment due to high demand. That means that not all start-up concepts are implemented or only on a low level. New instruments and the return of established VC corporations are therefore urgently required. The many public investors, such as HTGF, KFW, with its ERP-Startfonds, and IBB Bet on a regional level, provide advance funding, but cannot meet the demand for finance future funding rounds on their own. 11
BioTOPics 44 | May 2012 BioTOP-Report Industry
Excellent Services for the Business Location Berlin-Brandenburg Due to its high concentration of science and research establishments, the region offers outstanding potential for technological development and cooperation. The joint Life Sciences Team from the Berlin Partner business development agency and the Brandenburg Economic Development Board ZAB supports the life science industry with a full range of services, including marketing activities at national and international exhibitions. In addition, the Life Science Screening Package Berlin-Brandenburg tends to the needs of major companies in the biotech sector. This program supports companies who seek business partners, networks, service providers and research institutions. In 2011, the Berlin Partner Life Sciences Team supported expansion projects and provided location services to 17 companies in the capital city, including B. Braun Melsungen AG which started a second expansion at its site in Berlin. More than 1000 new jobs will be created in the next three years with these projects. In the field of life sciences, ZAB supported more than 70 investment and innovation projects in Brandenburg and was able to assist health industry companies like Laserneedle GmbH, a medical tech business, in moving to the region in 2011. In addition, GETEMED AG expanded at its site. Pentracor and Immunservice GmbH were further examples of how R&D projects are successfully implemented in Brandenburg.
Contacts: The German Capital Region at BIO-Europe Spring 2012 in Amsterdam.
Berlin-Brandenburg stands out in the life sciences because each health industry segment is present here: The high concentration of international excellence facilitates interdisciplinary exchange and makes it easier to achieve new landmark developments. At the same time, the sheer number of players can make it difficult to find the right partner. Our staff and colleagues at BioTOP have been in direct contact with the region’s companies and scientific institutions for many years and can provide quick access to the right contacts and potential partners. 12
Carolin Clement Head of Business Unit Life Sciences Berlin Partner GmbH Phone: +49 30 39980230 carolin.clement@berlin-partner.de www.berlin-partner.de
Dr. Ute Hartmann Head of Department Healthcare Industry/ Life Sciences Brandenburg Economic Development Board Phone: +49 331 6603838 ute.hartmann@zab-brandenburg.de www.zab-brandenburg.de
BioTOPics 44 | May 2012 BioTOP-Report
BIONNALE – Networking at the industry’s largest convention in the German Capital Region The annual BIONNALE – the Berlin-Brandenburg biotechnology industry’s most important convention – is also regarded as an ideal platform for gathering information about existing funding potential for biotech companies in the region, as well as learning about the latest scientific and economic developments. On the BIONNALE Venture Market, the BIONNALE Contact Forum and at the evening get-together, progress was achieved for a large number of partnerships, projects and funding agreements. This year, the BIONNALE has celebrated its 10th anniversary with more than 500 guests.
13
Getting your innovation going. Our tailored financing are your key to success. Our consultants look forward to meeting you.
Contact us: Phone: +49 (0)30 / 2125-4747 E-mail: wachsen@ibb.de www.ibb.de/wachsen
BioTOPics 44 | May 2012 BioTOP-Report
ORGANOBALANCE GmbH In Harmony with Nature ORGANOBALANCE exploits the potential of probiotic bacteria and yeasts for new product developments in food, feed, personal care, for the pharmaceutical industry and for the production of fine chemicals. From a large number of microorganisms, specific strains are selected to inactivate pathogenic microorganisms, add new activities, neutralize malodorous/toxic substances or produce high titers of valuable compounds.
ORGANOBALANCE relies on a variety of natural resources, which are gathered in a company-owned collection of 8000+ microbial strains, mostly originating from foodstuffs. ORGANOBALANCE uses its OASSYS® bioassays for highly efficient screenings. This platform allows the quick identification of most suitable strains from the microbial collection for new applications. ORGANOBALANCE has a broad expertise in the field of yeast metabolic engineering. This includes the design and development of new production strains for industrial biotechnology applications. Specific production strains of Saccharomyces cerevisiae, which carry engineered biosynthesis pathways for the environmentally friendly production of carboxylic acids, terpenoids, steroids and other lipid compounds are developed.
Address ORGANOBALANCE GmbH Gustav-Meyer-Allee 25 13355 Berlin · Germany Contact Dr. Christine Lang · CEO Phone +49 30 46307200 Fax +49 30 46307210 info@organobalance.com www.organobalance.com
ORGANOBALANCE works in exclusive collaboration with its partners and grants licenses for own product developments.
PAREXEL International PAREXEL International is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. For 30 years, PAREXEL has been committed to providing solutions that expedite time-to-market and peak-market penetration, bringing significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharma-
cology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. PAREXEL has a long-standing presence in Berlin, where over 1,500 employees are located. Clients can benefit from state-ofthe-art technologies and equipment provided through PAREXEL’s medical imaging lab and Early Phase Units, which provide a safe, high-quality environment for early phase development activities in a hospital setting. The PAREXEL Academy located in Berlin qualifies clinical research associates and clinical data managers, and offers a course for a Bachelor of Science degree in Clinical Research, validated by a British university.
Address PAREXEL International GmbH Klinikum Westend · Haus 18 Spandauer Damm 130 14050 Berlin · Germany Contact Dr. Ulf Schneider Senior Vice President and Chief Administrative Officer PAREXEL International Phone +49 30 30685 115 Fax +49 30 30685 7115 ulf.schneider@parexel.com www.parexel.com
15
BioTOPics 44 | May 2012 BioTOP-Report
ifp Institut für Produktqualität GmbH Founded in 2004, ifp Institut für Produkt qualität GmbH is an independent competence center for the analysis of food, feed, water and pharmaceuticals, offering a complete range of services. In addition, ifp develops and produces innovative products which are commercialized globally through a network of selected distribution partners. In 2012, ifp established a second laboratory center specialised in nutritional value and pesticide testing. The company currently employs 100 staff. Food Analytics The combination of expert staff, state-of-theart laboratory equipment and products specifically developed by ifp guarantees highquality analyses and competent service. The portfolio includes: kkAllergens: qualitative and quantitative allergen analytics; allergen management consulting kk Vitamins: determination of all water- and fat-soluble vitamins kk Microbiology: microbiological and molecular biological detection of microorganisms in food and drinking water. Additionally, ifp offers hygiene management consulting. kk GMO: screening, identification and quantification of genetically modified organisms kk Contaminants: analysis of mycotoxins, heavy metals, solvents etc. kk Nutritional value: analysis of the basic food components, e. g. water, fat, protein, carbohydrates etc. kk Residues: state-of-the-art analyses covering a broad spectrum of pesticides Ifp also offers extensive auditing, quality assurance, and control services covering the entire production process. The ifp Quality Seal is awarded to products that undergo and pass this examination.
16
parameters which are now available under the trademark mericonTM. The AgraStrip® product line includes immunological lateral flow tests for the rapid screening of allergens and is exclusively distributed globally by Romer Labs.
Pharma Analytics Ifp meets the highest demands not only in food analytics but also in the field of pharmaceuticals. The company has been GMP certified as per Section 14 (4) No. 3 of the German Drug Law, making it an official testing laboratory for subcontracted drug analyses in compliance with the Good Manufacturing Practice (GMP) guidelines. This authorizes ifp to carry out microbiological tests relevant for the release of pharmaceutical products. The services include testing for microbial purity of non-sterile medical products, testing for sufficient antimicrobial preservation and bacteria endotoxins, identification of microorganisms and analyses of water and monitoring samples. Innovative Products Several innovative product lines developed and produced by ifp are successfully distributed worldwide through renowned cooperation partners. The microtiter plate-based VitaFast® vitamin kits are distributed by R-Biopharm. In 2010, QIAGEN acquired the sales rights for ifp’s real-time PCR kits for the detection of pathogens, GMO, and other
In March 2011, ifp officially launched its fourth product line within five years, EnzymeFast®, for which ifp has been awarded the InterLabTec Award for Innovative Solutions for Analysis in Labs and Processing. More products are currently in the pipeline. Additionally, ifp is involved in several research projects. Address ifp Institut für Produktqualität GmbH Teltowkanalstraße 2 12247 Berlin · Germany Contact Dr. Wolfgang Weber General Manager Phone +49 30 766860 0 Fax +49 30 766860 50 www.produktqualitaet.com info@produktqualitaet.com
BioTOPics 44 | May 2012 BioTOP-Report
nanoPET Pharma GmbH nanoPET is a biopharmaceutical company specialized on R&D, manufacturing and marketing of innovative drug substances for Diagnostic Imaging. We focus on relevant cardiovascular, oncological and neurological indications as well as on regenerative medicine. Nanotechnology is a key element of our business. We operate in three major areas.
The first nanoparticular tracers for clinical PET: nanoPET prepares the clinical development of its patented technology platform: inorganic nanoparticular tracers for cell- and molecular-specific positron emission tomography (PET). Viscover™ imaging agents – a landmark in small animal imaging: As animal imaging is rapidly gaining relevance in pharmaceutical research, we are delighted to offer you an exciting portfolio of specialized preclinical imaging agents covering the principal imaging modalities (MRI, CT, Ultrasound, Optical Imaging, SPECT & PET). Get a detailed insight into our product portfolio and download a free copy of our imaging guide on www.viscover.com
long-standing industry expertise our team has attained in the pharmaceutical research & development. Address nanoPET Pharma GmbH Robert-Koch-Platz 4 10115 Berlin · Germany Contact Dr. Andreas Briel · CEO Phone +49 30 890 49740 imaging@nanopet-pharma.com www.nanopet-pharma.com
Consulting and Service tailored to your needs: As a technology and service provider, we offer our expertise to biopharmaceutical companies and imaging equipment manufacturers. Our customers benefit from the
Evestra GmbH Evestra GmbH, founded in July 2008, is a fully owned subsidiary of Evestra Inc. located in San Antonio Texas. Evestra GmbH serves as the development and commercialization center for Europe and ROW. Evestra’s mission is to develop and commercialize steroid-based female healthcare products. The development strategy of the company
includes product ideas with known compounds as well as New Chemical Entities. Evestra is conducting research and product development in a number of in-demand, but as yet unmet, medical need areas of women’s health such as hormonal-dependent breast cancer and endometriosis. The company is also pursuing different projects in fertility control, e.g. a new estrogen for oral contraception, with superior pharmacological properties compared to the standard drug ethinyl estradiol.
Address Evestra GmbH Britzer Straße 26 12439 Berlin · Germany EU Contact Prof. Klaus Nickisch · Managing Director Phone +49 30 66509642 knickisch@evestra.com www.evestra.com
Several patents on new composition of matter, new technical processes and use patents have been filed during the last three years and support the strong intellectually property position. Evestra is concentrating on R&D and will seek more partners for commercialization. More detailed information can be found on our web side.
17
BioTOPics 44 | May 2012 BioTOP-Report
Biotech Parks
The BioCampus Network Berlin-Brandenburg
Berlin-Brandenburg boasts seven biotechnology parks, which offer optimal space for the specific requirements of every company. This geographic concentration of specific biotech parks is unique in Germany and probably in all of Europe. The parks differ in their offers and strategic focus and provide ideal conditions for newcomers. More than half of the 215 companies are currently utilizing the infrastructure of a publicly or privately managed park. In addition, the young companies benefit from the closeness to science and the permanent contact and exchange.
berlinbiotechpark In the very heart of Berlin berlinbiotechpark is located on a 86,000 sq.m. site in the very heart of Berlin, currently offering a total of approx. 57,000 sq.m. of office, laboratory and production space, with a building potential for another 45,000 sq.m. of rental area. The site, which is home to 32 Biotech/Pharma/Service Companies is supplied with a complete range of media for laboratory and production purposes, with production steam with possibility to upgrade to HP steam, power supply, compressed-air, nitrogen and other inert gases, cooling water, DI-water, with possibility to upgrade to aqua purificata and water for injection, all being provided at favorable rates.
infrastructure, berlinbiotechpark is particularly attractive for growing internationally orientated technology companies. Furthermore, it offers a permanent base in Berlin for developing companies that have outgrown the size allowed by their limited start-up funding. The inner-city location and the excellent public transport guarantee short ways to all scientific institutions and hospitals of the city. berlinbiotechpark Tegeler Weg 33 · Max-Dohrn-Straße 8-10 · 10589 Berlin Phone +49 30 20364205 · Fax +49 30 20364190 info@berlinbiotechpark.de · www.berlinbiotechpark.de Contact: Ingo Schneemann
Biotech Campus Potsdam Research on the Waterfront Just a few minutes away from Potsdam’s central railway station in the direction of Caputh, Biotech Campus Potsdam is located on the Hermannswerder peninsula in the river Havel. It is owned and operated by Biotech Campus Potsdam GmbH, a fully owned subsidiary of the Investment Bank of the State of Brandenburg.
The infrastructure includes a canteen and conference facilities as well as works security and waste disposal services. It is rounded off by production-relatedservices such as plant engineers and laboratory technicians, industrial safety engineers, a medical service as well as best-buy services and communication services. Offering flexible growth potential, production-orientated media equipment and comprehensive industrial-specific services and 18
The biotechnology center is housed in four buildings dating from around 1900 and one modern complex and offers a total of 11,400 sq.m. of laboratory, office, greenhouse and storage space. With such a large facility at its disposal, it offers biotechnology companies an ideal environment for successful operations. All labs are approved as S1 laboratories and meet the building requirements for approval as S2 labs. The Hermannswerder site also includes an S3 laboratory as a special resource. The beautiful, park-like setting of the peninsula offers an excellent environment for research activities. The island hotel and a conference center are located directly next to the campus.
BioTOPics 44 | May 2012 Biotech Parks BioTOP-Report
The site also includes a self-service restaurant and small island shop. The philosophy of Biotech Campus Potsdam was, and still is, to create the freedom for research and innovation in the hightech sector of biotechnology. Reputable firms from the industry can indeed be found here.
The work carried out by resident companies is multi-faceted, ranging from green biotechnology, the development of vaccines, the development of pharmacologically active substances based on plant materials, the development and production of PCR tests for food testing and preclinical contract research right through to medical technology. A total of 200 employees work on the site. Biotech Campus Potsdam Steinstraße 104-106 · 14480 Potsdam Phone +49 331 6601628 · Fax +49 331 6601699 info@biotechcampus.de · www.biotechcampus.de Contact: Gabriele Ziegler
Biotechnology Park Luckenwalde Space for Expansion Located just 25 miles from the new Berlin-Brandenburg International Airport (BBI) in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one of the most modern facilities of its kind in Germany. It is home to 35 companies with 550 employees from Germany, USA, UK, Korea, India, Italy, Israel and Russia. Companies in the park focus on the development and production of pharmaceuticals, recombinant proteins and diagnostic kits,
biological/chemical substances for biotech and pharmaceutical applications, as well as fine chemicals. There are also suppliers of medical technology, analytical services, and a Biotech Education Center. Technical Equipment comprises completely furnished S2 laboratories (safety workbench, autoclave, dishwasher, deionized water, water purification system, central media supply (compressed air, N2, Co2, O2, H2), storage and cool rooms, pharmaceutical clean rooms category (B/C), 400 MHz NMR spectrometer, meeting rooms, conference hall (300 seats), library, restaurant with catering service.
The entire central technique meets GMP/ISO 9001 specifications. The park management offers comprehensive, individual services and advice during the settlement and development of firms, including support for the implementation of quality management systems and GMP certification. Currently the park offers 15.000 sq.m. labs and office space, and additional 100.000 sq.m. industrial property ready for expansion. Biotechnologiepark Luckenwalde · c/o SWFG mbH Im Biotechnologiepark, TGZ I · 14943 Luckenwalde Phone +49 3371 681100 · Fax +49 3371 681105 bio-luck@swfg.de · www.bio-luck.de Contact: Dipl.-Ing. Christoph Weber · Director
Co:bios Technologiezentrum Service for all stages of growth and expansion Located in the northwest of Berlin, the co:bios Technology Center in Hennigsdorf is the congested urban area in Berlin-Brandenburg of biotechnology and life science. In the last 15 years more 19
BioTOPics 44 | May 2012 BioTOP-Report Biotech Parks
than 30 companies with approximately 700 international employees have settled on this site.
Campus Berlin-Buch
On more than 10.000 sq.m. we offer service space for extension to clean rooms (class D/E/F), S1 labs, DI-water supply, compressed air supply, special gas supply, state of the art data communication, meeting rooms, conference hall and more. The building and central technique requirements also meet the fulfillments for S2 labs for GMP/ISO 9001 based production specifications. As a center of excellence for biotechnology and life science we have a selected portfolio of service and advice to young start-ups as well as medium sized companies, in aim to support them across all stages of company growth. For those companies who have outgrown their limited start-up funding, we additionally hold 80.000 sq.m. developed industrial property ready for expansion.
Berlin-Buch is the location of one of the largest biotechnology parks in Germany, with 26.000 sq.m. of scalable lab and office space for start-ups and maturing companies. Situated to the northeast of the city, the Berlin-Buch Campus is currently home to 54 companies, 35 of which are biotech companies; the rest provides support services.
With our holistic approach combining settlement, development, construction and licensing issues to the point of traditional management consulting, and on the background of the high density of innovative, research-intensive and service-oriented companies on the co:bios biotechnology park Hennigsdorf we can initiate interesting synergy effects for your business model. Within this locational advantages the co:bios biotechnology park became a magnet for the international healthcare industry and the percentage of international settlements on this site is growing, fore example from USA, South America, VAI and Asia. co:bios Technologiezentrum GmbH Neuendorfstraße 20 a · 16761 Hennigsdorf Phone +49 3302 2021250 · Fax +49 3302 2021257 info@cobios-technologiezentrum.de www.cobios-technologiezentrum.de 20
Interaction of Research, Clinics and Companies
Beside the BiotechPark the Max Delbrück Center for Molecular Medicine, the Leibniz Institute for Molecular Pharmacology as well as clinical groups from the Charité University Hospital within the Experimental and Clinical Research Center are part of the Campus community. The Campus gives access to high-end technology platforms, state of the art infrastructure, interdisciplinary communication, projects and expertise in a wide range of items, especially in translational research. The BiotechPark including the Innovation and Incubation Center is managed by BBB Management GmbH Campus Berlin-Buch. Acting as s full-service company BBB’s main tasks are the settlement, accompanying and support of Biotech businesses. The BiotechPark at the Campus Berlin-Buch offers: kk Immediately available lab and office space kk Excellent research and clinical expertise on-site kk Training programs for personnel on spot kk An international community of like-minded people kk Interdisciplinary networks and platforms Campus Berlin-Buch Robert-Rössle-Straße 10 · 13125 Berlin
BioTOPics 44 | May 2012 Biotech Parks BioTOP-Report
Phone +49 30 94892511 · Fax +49 30 94893812 info@bbb-berlin.de · www.bbb-berlin.de Contact: Dr. Andreas Mätzold · Executive Manager Dr. Ulrich Scheller · Executive Manager
Technical Equipment comprises laboratories with a basic equip ment:security-lockers, laboratory basins, work benches, vacuum supply, preliminary setup for supply of pure gases and compressed air, reconfiguration for further media and gases, central cooling, preliminary setup for cold water supply in rental areas, refitting of heat exchanger by the tenant possible.
Berlin Adlershof The “City of Science, Technology and Media” Berlin Adlershof is one of the most successful high-tech locations in Germany with focus on photonics and optical technologies, material and microsystems technology, information and media technology, as well as biological, environmental and energy technology. There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m. of lab and office space. The environmental, biological and energy technology companies focus on:
Adlershof Zentren für Biotechnologie und Umwelt WISTA-MANAGEMENT GMBH Rudower Chaussee 17 · 12489 Berlin Phone +49 30 63922221 · Fax +49 30 63922212 terytze@wista.de · www.adlershof.de Contact: Heidrun Terytze Head of Center for Biotechnology and Environment
Science Park Potsdam-Golm kkAnalysis: Tracing substances in foodstuffs and groundwater, cosmetics, waste; Quality assurance, Identification of pollutants kkBiotechnology: Research development and marketing or manu facture of base materials for biotechnology and chemical processes, of biochips and biochip-based biomedical procedures, of technical enzyme preparations kkEnvironmental technology: Remediation work based on innovative microbiological processes for degradation of pollutants or production of specific microbial anacultures; Research in the field of supercritical media and high-pressure technology;Highsensitivity detection systems for biotechnology and genetic engineering; Laser technology kkPharmacy, Medicine and Medical Technology: Equipment engineering and measurement technology; Research for medical chemistry
Connecting Excellence
Science Park Potsdam-Golm combines cutting-edge international research and the training of young scientists in a high-powered location in the immediate vicinity of the German capital Berlin. Alongside the Faculty of Science and the Human Sciences Faculty of the University of Potsdam, three Institutes of the Max Planck and two of the Fraunhofer Society as well as an innovation center with currently 18 companies operate in Brandenburg’s largest science park. More than 2500 people work at Potsdam-Golm and more than 8000 students are pursuing their academic qualifications here. The pleasant and very family-friendly working environment on the edge of a nature conservation area, the high quality of life 21
BioTOPics 44 | May 2012 BioTOP-Report Biotech Parks
in and around Potsdam and continuous growth make PotsdamGolm a highly attractive location. Professional site management is extending the park infrastructure and fosters the integration of the capabilities and interests of all institutions, associations and companies that operate at Science Park Potsdam-Golm. The GO:IN Innovation Center offers young technology-based companies and entrepreneurs a range of office and laboratory spaces along with extensive services and optimal support for a successful market launch. Close proximity to the other players at Potsdam-Golm and the intensive networking of the different institutions and companies here offer perfect conditions for the development and exploitation of synergies.
Standortmanagement Golm gGmbH GO:IN Golm Innovationszentrum GmbH Am Mühlenberg 11 · 14476 Potsdam-Golm Phone +49 331 237351130 www.wissenschaftspark-potsdam.de · www.goin-potsdam.de Contact: Friedrich W. Winskowski · Managing Director
Our experience is your success! The German Pharmaceutical Industry Association (BPI – Bundesverband der Pharmazeutischen Industrie e.V.) consists of approximately 260 pharmaceutical companies. These include not only the classic pharmaceutical firms and service-providers, but also biotechnology companies and manufacturers of medical devices.
All of our members use our association as a platform for information and communication to develop collaborative responses to the diverse challenges they face. Our team consists of highly qualified experts in all fields which are necessary to generate a sustainable benefit for pharmaceutical companies, e.g. market access, regulatory affairs, law, biotechnology and political affairs. Interested in being a member? Feel free to contact us! info@bpi.de · www.bpi.de · Phone: +49 – 30 – 27909 – 0 Start Up-Companies are eligible for reduced membership fees while having the possibility to participate in all activities of our association.
22
Expertise in Life Sciences Special
Industrial Biotechnology 2012 (Vol. 3) February 25th, 2012
Publication date:
Supplement
Healthcare 2012 (Vol. 6) March 31st, 2012
Publication date:
Special Topic Life Science in
GoingPublic Magazin 7/2012 Publication date:
June 30th, 2012
Advertising close:
June 18th, 2012
Special edition
Biotechnology 2012 (Vol. 14) Publication Date:
September 15th, 2012
Advertising close:
September 3rd, 2012
s blic´ u P ng Goi lassic c
Supplement
Medical Technology 2012 (Vol. 10) Publication date:
November 14th, 2012
Advertising close:
November 2nd, 2012
Contact media sales team Daniela Gebauer
Tel. +49 (0) 89-2000 339-13
gebauer@goingpublic.de
Katharina Meindl
Tel. +49 (0) 89-2000 339-53
meindl@goingpublic.de
Karin Hofelich
Tel. +49 (0) 89-2000 339-54 Tel. +49 (0) 177-422 52 89
karin.hofelich@goingpublic.de
Only GoingPublic Magazin’s Special “Industrial Biotechnology” is published in English, all others in German. Further info: www.goingpublic.de
BioTOPics 44 | May 2012 BioTOP-Report
Life Sciences
Excellent Research in Berlin-Brandenburg
Berlin-Brandenburg is regarded both nationally and internationally as one of the most important centers of modern biotechnology. The region provides optimal conditions: It is one of the TOP life sciences locations worldwide – with five universities, numerous colleges and a unique density of extramural research centers. Renowned facilities in the field of biotechnology and the life sciences include four Max Planck Institutes, two Fraunhofer Institutes, two Leibniz Institutes and two Helmholtz Association centers. The region also has an abundant landscape of clinics, led by the Charité – Universitätsmedizin Berlin.
Biotechnology is a major contributor to the development of the modern life sciences. It is highly interdisciplinary, encompassing pharmaceutics research, diagnostics, theranostics, molecular genetics and the development of innovative biomaterials for medical applications. In addition to scientific expertise, the Berlin-Brandenburg region offers excellent conditions for close networking between different science disciplines, research centers, industry and (clinical) users. No less than seven technology parks focusing on the life sciences are situated in the region (see p. 18-22). One of Germany’s largest biotechnology parks is Campus Berlin-Buch, with important facilities such as the Max Delbrück Center for Molecular Medicine (MDC), which is part of the Helmholtz Association, and the Leib-
JANUARY 2011 Prof. Dr. Andreas Radbruch of the German Rheumatism Research Center Berlin (DRFZ) receives Advanced Grant of the E uropean Research Council (ERC) in the amount of 2.5 million Euro ++++ Prof. Dr. Klaus Rajewsky receives Advanced Grant of the European Research Council (ERC) in the amount of 2.5 million Euro and establishes working group at the MDC
FEBRUARY 2011 ESGI project (the European Sequencing and Genotyping Infrastructure), coordinated by the Max-Planck-Institute for Molecular Genetics, starts
MARCH 2011 Charité-scientist Andrea Ode of the Julius Wolff Institute wins BIONNALE Speed Lecture Award ++++ Prof. Dr. Oliver Daumke from the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch receives “Bayer Early Excellence in Science Award 2010” for biology
APRIL 2011 Berlin research consortium becomes part of the German Center for Cardiovascular Research (DZHK) ++++ Dr. Daniel Toben of Charité receives Raisz-Drezner-Award of the American Society of Bone and Mineral Research (ASBMR) ++++ BioTOP and BCRT publish technology report on Regenerative
24
Prof. Dr. Volker Haucke Scientific Director of the Leibniz Institute for Molecular Pharmacology (FMP)
We are experiencing exciting times in Berlin and at the Campus Buch, where biology, pharmacology, and chemistry meet – with the FMP serving as a melting pot. The Campus and the FMP have gained a lot of international recognition over the last years and serve as a magnet for top scientists from all around the globe.
Medicine in Berlin-Brandenburg ++++ Prof. Dr. Jan Schwab of the Department of Neurology at the Charité and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) received the Novartis Award for therapy relevant pharmacological research
MAY 2011 Researchers at the Max Delbrück Center for Molecular Medicine (MDC) BerlinBuch of the Helmholtz Association have discovered what it is that enables embryonic stem cells to develop into the most diverse cell types and hence be pluripotent ++++ An international team around researchers at the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the bacterium Clostridium difficile, which causes severe intestinal infections especially in hospitals
JUNE 2011 The MDC, Charité and German Heart Institute Berlin (DHZB) are appointed as the Berlin sites for the German Centers for Cardiovascular Research (DZHK) ++++ Andreas Radbruch, Science Director of the German Rheumatism Research Center (DRFZ), receives the world’s most prestigious rheumatology award, the Carol-Nachman Prize, for his research into the immunological memory for inflammatory-rheumatic diseases
BioTOPics 44 | May 2012 Life Sciences BioTOP-Report
niz Institute for Molecular Pharmacology (FMP). Both institutes are celebrating their 20th anniversaries this year and enjoy an outstanding reputation worldwide. Chemists, biologist, bioinformaticians, pharmacologists, pharmacists, physicists and doctors work together from around the world. It is clear that the German Capital Region is becoming ever more attractive to scientists due to its excellent research and living conditions.
sociation, thereby consolidating the leading international position of Berlin-Brandenburg as a life science location in the long term.
Prof. Dr. Walter Rosenthal Science Director of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Pooling fundamental and patient-oriented research The significance to biomedical research in the German Capital Region is further enhanced by the close cooperation between the Charité and the MDC. There are also plans to further extend the pooled complementary fundamental and patient-oriented clinical research on an institutional level by creating a joint research as-
Prof. Dr. Jürgen Mlynek President of the Helmholtz Association
JULY 2011 Berlin achieves yet another success for health research: the Charité is selected as the new site of the German Research Institute for Neurodegenerative Diseases (DZNE) ++++ Research at the MDC in the field of pharmaceuticals research will from now on be networked closely with five other centers of the Helmholtz Association of German Research Centers and three other partners, including the Leibniz Institute for Molecular Pharmacology (FMP) in BerlinBuch
AUGUST 2011 The Berlin Institute for Medical Systems Biology (BIMSB) of the MDC is now the first academic research facility on the European continent to receive an innovative sequencing system using SMRT technology which can read individual DNA molecules in real-time ++++ Charité has established the new molecular diagnostic test ”EndoPredict Assay” for breast cancer patients which helps doctors in deciding which personalised therapy to choose for individual patients
SEPTEMBER 2011 Prof. Dr. Thomas Willnow at the MDC is awarded the Franz-Volhard Prize on September 10, 2011 at the opening ceremony of the annual conference of
The new structure will be most beneficial for both the MDC and the Charité since excellent basic research and excellent clinical research will further strengthen and complement each other for the benefit of patients. And it goes without saying that excellence is the key to success.
The planned strategic partnership between the MDC and the Charité will give biomedical research in Berlin an even higher international profile.
the German Society of Nephrology in Berlin ++++ Researchers at the MDC in Berlin-Buch establish the first mathematical model for determination of the contribution of genetic risk factors to the development of Alzheimer’s ++++ The Charité opens the new building for its Translation Research Institutes: the facility’s central unit is the Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
OCTOBER 2011 The scientist Dr. Jan Laufer receives 1.6 million Euros from the European Research Council (ERC) to establish a researcher group for the investigation of stem cells in tissue regeneration by means of photoacoustic imaging
NOVEMBER 2011 In the context of the internally funded project „Fraunhofer ivD-Plattform“ a credit-card sized system was developed jointly by seven Fraunhofer Institutes during the past five years which now permits the analysis of up to 500 parameters in a single drop of blood ++++ Four researchers at the MDC will receive a total of eight million Euros in research funding from the European Research Council (ERC) in Strasbourg. The two neurobiologists Prof. Dr. Gary Lewin (MDC) and Prof. Dr. Thomas Jentsch (MDC/FMP) will each receive an ERC Advanced Grant worth 2.5 million Euros
25
BioTOPics 44 | May 2012 BioTOP-Report Life Sciences
Outstanding research to meet the medical and bioeconomic challenges of the future There are also many excellent research facilities in the state of Brandenburg – including the University of Potsdam, the Helmholtz-Zentrum Geesthacht in Teltow, the Fraunhofer Institute for Applied Polymer Research, the Fraunhofer Institute for Biomedical Engineering, the Max Planck Institute for Colloids and Interfaces, the German Institute for Human Nutrition and the Max Planck Institute for Molecular Plant Physiology. In addition to red biotechnology, scientists also work on central aspects of green and white biotechnology, which are decisive for meeting
DECEMBER 2011 Prof. Dr. Nikolaus Rajewsky at the MDC receives the Gottfried Wilhelm Leibniz Prize, Germany’s most highly endowed science award ++++ The scientist Dr. Alexander Kühn at the Max Planck Institute for Molecular Genetics is this year’s winner of the essay competition “Gesundheit 2050”
JANUARY 2012 Researchers at the MDC map the mechanism by which immunocyte cells destroy cancer cells ++++ Opening of the new Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine” ++++ Artemisinin, the most effective anti-malaria agent, can now be manufactured cheaply and in high volumes. Researchers at the Max Planck Institute for Colloids and Interfaces in Potsdam and from Freie Universität Berlin have developed a very simple artemisinin synthesis
FEBRUARY 2012 Scientists at the Charité are the first to have mapped which specific disorders of nerve cells are involved in the development of focal therapy-resistant epilepsies ++++ Prof. Dr. Erich Wanker at the MDC in Berlin-Buch will receive 1.35 million Euros over the next two years to search for active agents for the treatment of diseases caused by protein misfolding such as Alzheimer’s and Parkinson’s ++++ The Charité launches the new EU research project RESPONSIFY for
26
the bioeconomical challenges of the future. Modern biotechnology and life sciences create ever greater data volumes that cannot be managed without modern software solutions. So it is an advantage that two important software institutes, namely the Hasso-Plattner-Institut and the future SAP Innovation Center in Potsdam, are based locally and directly focus on the requirements of scientists and users in the region, developing innovative software technologies in close collaboration with them. The following pages present selected life sciences themes and projects in Berlin-Brandenburg and innovative developments achieved in the recent past.
improved adjustment of breast cancer therapy to each individual patient so as to avoid unsuccessful treatment
MARCH 2012 TU Berlin, the Science and Technology Park Berlin Adlershof and Campus Berlin-Buch launch a cooperation project with the Russian Skolkowo Foundation ++++ Scientists at the Charité and the US National Institutes of Health (NIH) developed a realistic model for cellular signal processes to permit systems biology analysis of the function of cardiac muscle cells and for modelling specific data from tumour tissues of lung cancer patients
Medical knowledge is our fascination. Together with our associates in research, science and education we help millions of people all over the world. We are obliged by our medical improvement, because health matters!
www.sanofi.de
AVS 903 12 013
Here for you. for your HealtH.
BioTOPics 44 | May 2012 BioTOP-Report
Theranostics
A New Approach in Individualized Healthcare for the Future The term theranostics refers the increasing integration of diagnostics and therapy with the aim of providing the right therapy for the right patient at the right point in time. The implementation of such a concept requires, above all, determination of the genetic predisposition of the patient, characterization of the stage of the disease and monitoring of the progress of healing. In vitro-diagnostic procedures and molecular imaging will increasingly interlock in this approach in the future.
Companion diagnostics and personalized medicine This “personalization” of medicine has become one of the prime strategic goals in health research. It is based on the insight that different patients with the same diagnosis respond differently to the same treatment. To choose the “right therapy”, it is therefore necessary first to evaluate a therapy potentially to be applied by reference to the individual patient and assess its effectiveness, tolerability, safety and dosage. This is done using predictive diagnostic tests which determine the individual features of the patient at the genetic, molecular or cellular level. The use of such companion diagnostics as part of the therapeutic process permits stratifying patients with the same diagnosis and selecting them accordingly to ensure that each patient receives the most effective customised therapy possible. Personalized medicine consequently comprises defined tandems of medicines and tests to demonstrate effectiveness of the respective therapy. The key drivers behind this trend are, above all, the need to improve medical treatment (healthcare pressure/benefit-risk ratio), economic pressure (benefit-cost ratio) and the development of new technologies which continuously expand the range of diagnostic capabilities available.
The impact of new technologies on the development of personalized medicine Diagnostics for personalized medicine require suitable biomarkers as the foundation for patient-specific therapy selection. The sequencing of the human genome and the continuously progressing molecular differentiation it has opened up, above all as regards oncological and immunological diseases, permits predictive statements about the possible progress of therapy based on an analysis of the patient’s genetic makeup. Next generation 28
sequencing, bioinformatics and data mining are expanding the range of available markers continuously. The Max Planck Institute for Molecular Genetics, the spin-off company Alacris Theranostics GmbH and Bayer Healthcare are eminent players in this field in Berlin-Brandenburg in the context of the European research project OncoTrack which focuses on cancer of the colon. The miniaturization and parallelization of analytical technologies (micro-arrays, beads) and new multiplex processes such as those developed by Scienion AG (Berlin) and the Fraunhofer Institute for Biomedical Engineering (IBMT) in Potsdam are bringing the new assays into routine clinical laboratory practice.
Oncology – key driver for diagnostic-based therapy The approval of Trastuzumab in the United States in 1998, based on the genetic proof of the overexpression of the HER2 gene in breast cancer, marked the first step in the personalization of oncotherapy. Since then, further genetic tests have been introduced into clinical practice, including K-RAS (colorectal cancer) and EGFR mutation analyses (lung cancer). The approval of new and expensive medicinal substances such as biologicals will be conditional in future on the availability of mandatory diagnostic pre-tests. In Germany, 20 medicines are currently approved for personalised medicine, 16 of them for oncotherapy and the rest for the treatment of HIV (2), epilepsy (1) and transplantation prognosis (1). The co-development of diagnostic and therapeutic products presents the pharmaceutical industry with a new strategic challenge and is opening up new business fields for innovative SMEs as developers of in vitro-diagnostics.
BioTOPics 44 | May 2012 Theranostics BioTOP-Report
In vitro-diagnostics in Berlin-Brandenburg In Berlin-Brandenburg, some 80 SMEs and about 20 research facilities provide the entire value chain for in vitro-diagnostics – from biomarker identification and validation to the development of new technologies for the production of marketable innovative products, above all for immunology, oncology and the diagnosis of infectious diseases. As one of Europe’s largest university hospitals, Charité – Universitätsmedizin Berlin provides outstanding conditions for the implementation of clinical trials to validate new biomarkers. Some 30 regional companies specialise in the development of molecular diagnostics for use in screening, prognosis and monitoring, and some of them are also engaged in the development of companion diagnostics for oncotherapy. Current developments include assays for the therapy of cervical cancer under anti-angiogenesis treatment (Celltrend GmbH, Luckenwalde), for the use of Cetuximab in colorectal cancer therapy (Signature DIAGNOSTICS GmbH, Potsdam), the develop-
ment of mathematical models for the implementation of “virtual” clinical studies and the discovery of new markers in colon and pancreas cancer therapy (Alacris Theranostics GmbH/Berlin). PD Dr. Bodo Lange CEO Alacris Theranostics GmbH Berlin
Personalised healthcare is currently undergoing a revolutionary development as technology advancement permits now to analyse a patient's genome with increasing speed at continuously falling costs. Alacris Theranostics is applying a combination of next generation sequencing and systems biology modelling to develop new methods for optimised personalized treatment of cancer patients. The Berlin-Brandenburg academic research and biotech network provides an excellent environment for such developments.
29
BioTOPics 44 | May 2012 BioTOP-Report
Health-IT
New Opportunities for Biotechnology on the Interface between Life Sciences and IT Berlin-Brandenburg is not only one of Europe’s most attractive life sciences and healthcare locations, but also a leading centre of the IT industry. That combination offers optimal conditions for the development of innovative health IT solutions for the regional and global market. To bring together the know-how of the different sectors involved and promote even stronger networking between the players in the region, TSB Innovationsagentur Berlin organised a workshop on “Health IT Solutions for the Healthcare Industries of the Future” in cooperation with SAP and the Hasso Plattner Institute in late November 20111.
The participants, representing science and industry, jointly developed interdisciplinary scenarios of what regional model projects for innovative IT-supported healthcare may be seen by 2020. Several ideas from the workshop were adopted and are to be developed in working groups in the years ahead. Health IT comprises a broad range of applications, including telemedicine and solutions for process optimisation in hospitals as well as technologies for handling large data volumes along the entire value chain from research to patient therapy and care. Below we present some examples of projects in the Berlin region to illustrate what is happening on the interface between life sciences and IT.
IT Future of Medicine (ITFoM) – Berlin heads a European flagship project Modern biotechnology and today’s increasingly personalised medicine require a huge amount of fundamental data. That will present the IT sector with unprecedented challenges regarding hardware, software, memory and communication systems. To meet these new tasks in the clinical, technological and ICT-based environment, 60 mainly European institutions and companies have joined forces in the initiative “IT Future of Medicine” which is being coordinated by the Max Planck Institute for Molecular Genetics in Berlin. ITFoM will develop computer models by which personalised “virtual patients” will be derived from the molecular, physiological, anatomic and environmental data of every individual patient. The aim is to develop individually optimised prevention and therapy concepts and minimise the potential side-effects of therapies (more information: www.itfom.eu).
1
30
Documentation of the workshop for downloading at www.tsb-berlin.de/health-it
Prof. Dr. Hans Lehrach Director of the Max Planck Institute for Molecular Genetics
Medicine will in future be based on the ever larger volumes of available patient data. A small arithmetical example: At the MPIMG we need 12 hours of computing performance to simulate a tumour based on our cancer model which demonstrates the interaction of about 4000 cell components. In the case of a fully virtual patient, we would be talking about more than 1000 different cell types, each with 1000 different conditions! This can be done only with smaller chips, optimised data flows and smarter algorithms which increase the available computing capacity!
Using bioinformatics to develop a better understanding of life Bioinformatics is indispensable to catalogue, analyse and interpret the huge data volumes in medical research, genomics and systems biology. Many questions can simply not be answered without innovative computer programmes and mathematical methods. “Treffpunkt Bioinformatik” is a leading expert forum in this field. It is organised jointly every year by the Max Planck Institute for Molecular Genetics and BioTOP Berlin-Brandenburg in the German Capital Region. Its eighth meeting in September 2011 was attended by experts from Germany and the United States and devoted to “Bioinformatics and Evolution Biology“.
BioTOPics 44 | May 2012 Health-IT BioTOP-Report
Cafer Tosun Managing Director SAP Innovation Center
With the HANA Oncolyzer, SAP is also to some extent embarking into new territories beyond the field of “classical” SAP applications. This mobile application is helping oncology move towards personalised cancer therapy by providing a solution that can cope with the enormous flood of data and information. Until now, doctors wanting to use a promising personalised therapy need to research files and other documents for up to two days to find the patient whose features are suited for precisely that treatment. Using in-memory technology per iPad, this can now be done in just seconds. At the same time, the joint project HANA Oncolyzer with the Charité and HPI is a perfect example of how we at the SAP Innovation Center operate. We work directly with users because they are most familiar with the challenges in their field and with research facilities with a high international reputation like the HPI. In Berlin-Brandenburg we have exactly the kind of network that brings together leading experts like these. The HANA Oncolyzer demonstrates very impressively how fast such an initiative can deliver excellent results.
cancer within only seven months. The HANA Oncolyzer is based on the in-memory technology co-developed at the Hasso Plattner Institute which permits accessing all relevant patient and clinical data in realtime and supplementing them at any time. Using the mobile end user device, this can be done directly from the patient bed. Cancer therapies can therefore now be adjusted more specifically and more quickly to each patient and cancer type, so that the chances of healing improve considerably. In addition, this technology also makes the work of researchers far less onerous. For example in gene sequencing where terabyte volumes of raw data per patient are generated, the HANA Oncolyzer helps analyse them as to their relevance and select them accordingly. The HANA Oncolyzer was presented to a broad expert audience at CeBIT in spring 2012. Productive operation is scheduled to begin this year.
One of the themes addressed was how bioinformatics supports evolution biologists in reconstructing the emergence of presentday organisms and decoding the evolution processes involved. By sequencing the genomes of many species and analysing them applying IT-supported methods, scientists are working on the reconstruction of phylogenesis and thereby developing a better understanding of life.
A mobile application for personalised cancer therapy from Berlin-Brandenburg In the context of a joint research initiative, Charité – Universitätsmedizin Berlin, together with the SAP Innovation Center and the Hasso Plattner Institute in Potsdam developed a new data management technology for the research and therapy of
Figures: Analytical view of HANA Oncolyzer (Source: SAP AG)
31
BioTOPics 44 | May 2012 BioTOP-Report
Biomaterials
Biotechnologically Improved Biomaterials from Berlin and Brandenburg For decades, biomaterials have been an integral part of medical practice. The biologisation of biomaterials, however, is a relatively new trend. Multifunctional polymer-based biomaterials are of high relevance, especially in biomaterial induced auto-regeneration. Berlin-Brandenburg is positioned excellently in the material sciences field and is rapidly becoming a pacemaker for the newest generation of innovative biomaterials.
A great deal is happening in this field in the German Capital Region. Scientists at acclaimed institutions like the Max Planck Institute of Colloids and Interfaces, the Fraunhofer Institute for Applied Polymer Research, the Centre for Biomaterial Development of the HZG in Teltow, and Charité – Universitätsmedizin Berlin are setting international standards in this field. The outstanding networking between science and industry in the region permits swift translation of the latest research findings into marketable products. Alongside the big players in industry, small and midsized companies which often emerged as university spin-offs play a major role in these trailblazing activities. A prime example of networked cooperation in the region is the Helmholtz Virtual Institute (HVI) “Multifunctional Biomaterials for Medicine” which was opened in December 2011. The HVI “Multifunctional Materials for Medicine” is coordinated by the
Helmholtz Virtual Institute (HVI) Multifunctional Materials for Medicine Core Institutions kk Helmholtz–Zentrum Geesthacht (HZG-Teltow), Coordinating Centre HVI spokesperson: Prof. Dr. Andreas Lendlein kk Helmholtz-Zentrum Berlin (HZB) HVI deputy spokesperson: Prof. Dr. Matthias Ballauff kk Freie Universität Berlin (FUB/FUB-Charité) HVI deputy spokesperson: Prof. Dr. Rainer Haag kk Albert-Ludwigs-Universität Freiburg Prof. Dr. Prasad Shastri
International Partners Prof. Dr. Andreas Lendlein Centre for Biomaterial Development and Berlin-Brandenburg Centre for Regenerative Therapies · Helmholtz-Zentrum Geesthacht Spokesperson of the HVI
kk Harvard University, Materials Research Science and Engineering Centre, Cambridge (MA, USA) The University of Tokyo, Centre for NanoBio Integration, kk Tokyo ( Japan) kk Sichuan University, National Centre for Biomaterials, Chengdu (China)
Industrial Partners Helmholtz Virtual Institutes, funded by the Helmholtz-Association of German Research Centres were initiated to combine the key competencies of a university with those of one or two Helmholtz-Centres. Freie Universität Berlin, HelmholtzZentrum Berlin and HZG-Teltow are working together in the HVI “Multifunctional Materials for Medicine” with the aim to gain a comprehensive understanding of the complex proteinbiomaterial surface interactions in order to control the application-relevant protein adsorption behavior in the future. Our activities are integrated into the regional cluster "Healthcare Industries Berlin-Brandenburg – HealthCapital".
32
kk mivenion GmbH, Berlin kk Fresenius Medical Care Deutschland GmbH, Bad Homburg
Contact Prof. Dr. Andreas Lendlein Zentrum für Biomaterialentwicklung Helmholtz-Zentrum Geesthacht Kantstraße 55 14513 Teltow-Seehof Phone: +49 3328 352450 andreas.lendlein@hzg.de
BioTOPics 44 | May 2012 Biomaterials BioTOP-Report
“Centre for Biomaterial Development” at the Helmholtz-Zentrum Geesthacht/Campus Teltow (HZG-Teltow) and is one of twelve new HVI initiatives, which were successfully evaluated in a highly competitive process in July 2011.
Biomaterials in Regenerative Medicine With the Centre for Biomaterial Development at the HZG-Teltow and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), the German Capital Region has excellent expertise in the field of Regenerative Medicine. Here, fundamental research for polymer based biomaterials meets application-motivated science aiming at the translation of the knowledge gained into products and clinical applications. Cooperation of scientists from different disciplines is essential to perform research and develop bioma-
terials directed to clinical applications and products. This is the aim of the BCRT as one of the centres for translational research of the German Federal Ministry of Education and Research. This joint initiative of Europe’s largest university hospital, the Charité, and Germany’s largest research organization, the Helmholtz Association, is based on a highly interactive research program and a consortium of internationally acknowledged experts in both basic and clinical science with more than 15 excellent institutional partners.
The German Capital Region as pacemaker for innovative biomaterials There are other successful examples for biomaterials research in Berlin-Brandenburg, such as the cooperation of the research
Berlin/Bremen/Cologne/Frankfurt/Hamburg/Munich/Stuttgart
Life sciences companies are in safe hands with UHY. UHY Deutschland AG is a joint venture of long established medium-sized auditing and consulting firms with a total of 250 employees and partners.
UHY Deutschland AG has extensive experience in financial and consulting services for life sciences companies for many years. We offer the following services:
As a member of UHY International, a global association of independent accounting and consulting firms with about 6,800 employees we can provide audit, accounting, tax and consulting services in 250 business centres across the globe.
p pAudits of financial and consolidated statements under the German Commercial Code (HGB) and IFRS p pAccounting & Reporting p pDue diligence (financial and tax) and business valuations p pConsulting services on IPOs p pBusiness Advisory p pMergers & Acquisitions (M&A) p pGerman and international taxation
Contact
Dr. Ulla Peters or Reinhold Lauer UHY Deutschland AG Wirtschaftsprüfungsgesellschaft/Zimmerstraße 23/D-10969 Berlin 33 Phone +49 30 226593-0/Fax +49 30 22679050/www.uhy-deutschland.de/www.uhy.com
BioTOPics 44 | May 2012 BioTOP-Report Biomaterials
Financing and Added Value
VC Fonds Technologie Berlin group headed by Prof. Dr. Rainer Haag at Freie Universität Berlin with mivenion GmbH on the research campus Dahlem, which has successfully characterized a new macromolecular diagnostic agent for inflammation imaging of rheumatoid arthritis. The Nanopatterned Biomaterials group of Prof. Dr. Marga Lensen at the Technical University Berlin has developed a toolbox of tailor-made biomaterials that are patternable in 2D and 3D and at different length scales, and have tuneable physicochemical properties, specific degradability profiles and all the characteristics of a desired biomaterial. In addition, the Fraunhofer IAP specializes in the targeted development of sustainable processes and materials based on natural and synthetic polymers. The working group of Dr. Joachim Storsberg is developing an artificial cornea based on new biomaterials in order to obtain the different functionalities required to perform the needed biological interactions. The bone healing process can be supported by biochemical or mechanical intervention and by the introduction of synthetic scaffolds. In the Department of Biomaterials at the Max Planck Institute of Colloids and Interfaces in Potsdam, scientists are investigating the material characteristics of bones at the micro- and nanometer level. The research group of Britt Wildemann at the Julius Wolff Institute of the Charité in Berlin has studied the possibilities for improving bone healing by local application of factors. Antibiotics are used for infection prevention, while factors stimulating the bone metabolism are applied to promote healing.
Venture Capital for companies in Berlin IBB Beteiligungsgesellschaft mbH offers equity financing for high tech companies in Berlin. For our fund VC Fonds Technologie Berlin (€52m) we are looking for investment opportunities in the biotechnology and medical technology sector. Our investment approach is based on hands-on involvement and active management support for each portfolio company, delivered by our highly experienced investment team. VC Fonds Technologie Berlin not only provides capital, but also helps execute the business plan. Are you interested? Please do not hesitate to contact us. IBB Beteiligungsgesellschaft mbH Mrs. Ute Mercker / Mr. Christian Seegers Bundesallee 171 10715 Berlin / Germany Phone: +49 (0)30 2125-3201 www.ibb-bet.de
Another example of the use of biomaterials in medicine is the development of artificial heart valves. Such valves made by AutoTissue GmbH were produced by removing cellular components from xenogenic heart valves and have the major advantage that they do not calcify in vivo and possess remodelling and growth potential. Selected portfolio companies: Biomaterials are also essential in the field of drug delivery. For example, the Paccocath technology for the use of balloon catheters as an effective drug delivery technology was invented in the Department of Radiology at the Charité, then successfully developed to market maturity in cooperation with InnoRa GmbH and Saarland University, and is now being marketed by two companies. 34
VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank Berlin (IBB) and the State of Berlin. It is co-financed by the European Regional Development Fund (ERDF).
BioTOP-Report-2012_Anz_IBB-Bet_87x244.indd 1
30.03.2012 10:42:17
A AT GGA AT C G TA TA A CCA AG G GTT TCC ACA GCC TGA GCC G AT AT C G TA AG G GA A CAC CGA GCC CAA AGC ACC TA A AGT GTT
T G A CAC ACG T TC GCC C C A T C A C G A TA A A A C GA A ACC GA A TCA GCC T T G CA A GGC CAC CAG AC T GGA ACA AGA TCC STudieS & ConSulTinG T T C G TA T T A A C T A G A ConferenCeS AAG G A G CTC CTG GCG GTG TCA BookST C T C G C C A TA A ACG G A A A C G G G T G A C T V & VideoA C T C C G C A TA G G C T C A A A AC G C A CorporATe puBliShinG C A G C T T A C C AGA T G C inTerneT C T C C G C A C G G T T T C C A C A GCC T G A MAGAzineSG A T T C G T C T C A ACC CA A GGA G T T e V enT MAnAGeMenT T A A AC GCC CAG TCC AT T CAC GCT G T T CCC GGA G G C AAA G C A C A T C C A GGC GCA T G T T GA CAC G C T AGA CA A ACA T C T G T T C T C A AG GA A TGA A C T A C G T C C T G C AT G
BIOCOM AG | Lützowstraße 33–36 | 10785 Berlin | Germany www.biocom.de | Tel. +49 (0)30 264921-0 | Fax +49 (0)30 264921-11
G AT A A G G A A G T T AT G G A A GGA C A A T TA C C C G AT T G G AGT CA A GA A G C T T TC GAC TA G C A C A C G T G C G G A A C G AAA G C T T A T T G G A A G T G C G C A TA C C A A T G C AT G C A C G AT C AT T C T A A C C C T T A T AT C C C C T T G A C C GGC C G G A AT C A G T G A C G A C C G T G T C G T T G G C T T A A A G C T TA G G G G A AT C C A A C C GAC A G A C A T T T G C G A G C T A G A ACG T G T G C C G AT C A A G A A T G C T T T G G A GA A C T A A C A T C T A AG AT C T T G G G A G G C A C T T C C A AT G G A AT C G T A TA A G C C G A T AT C G TA AG G T G A C T C A G T ACG T C A TA G C A A G TA C TA C T G C G C G A A C T T GCG TCG ACG CAC CA A T G C AGA GAG TCA TA A GAC GCA T G C A C A G C C AG G A C T C T T AGA GA A TGG GAC ACG TGC A AT C A G C C T G A T TA G C A C W e C r e AT e k n o W l e d G e ! CGA T G T GCC T T G ACC TCG T T G CGA T T G GGA AGA A A A
CCT AAA TGC ACA CCG GGA AGC TTT ACA GCC AT T TA A A AG AGA GAG CCA CAA ACT ACG ACC GCA TGC CAC CAG TGG ACG CTC
BioTOPics 44 | May 2012 BioTOP-Report
P Bioparks etworks P NScientific P CompaniesInstitutions P
Biotech Networks kkBioTOP Berlin-Brandenburg kkBioHyTec Network for Biohybrid Technologies kkBioResponse kkCenter for Molecular Diagnostics and Bioanalytics (ZMDB) kkDiagnostikNet-BB kkGABI – Genome Analysis in the Plant Biological System kkNetDDD Network for Drug Discovery & Development Berlin-Brandenburg kkNetwork Glycobiotechology Berlin-Brandenburg kkNutrigenomics Network Berlin-Brandenburg kkRegenerative Medicines Initiative Berlin-Brandenburg kkRiNA Network for RNA Technologies Scientific Institutions kkBerlin-Brandenburg Center for Regenerative Therapies kkBerlin Institute of Technology kkBrandenburg University of Technology kkCharité – Universitätsmedizin Berlin kkFraunhofer Institute for Applied Polymer Research kkFraunhofer Institute for Biomedical Engineering (IBMT) kkFreie Universität Berlin kkGerman Heart Instiute Berlin kkGerman Institute of Human Nutrition (DIfE) kkGerman Rheumatism Research Center (DRFZ) kkHumboldt-Universität zu Berlin kkInstitute of Polymer Research of the GKSS Research Centre kkLausitz University of Applied Sciences kkLeibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB) kkLeibniz-Institut für Molekulare Pharmakologie (FMP) kkLeibniz-Zentrum für Agrarlandschaftsforschung (ZALF) e. V. kkMax Delbrück Center for Molecular Medicine (MDC) Berlin-Buch kkMax-Planck-Institute for Colloids and Interfaces kkMax Planck Institute for Infection Biology kkMax Planck Institute for Molecular Genetics kkMax Planck Institute of Molecular Plant Physiology kkRobert Koch Institute kkUniversity of Applied Sciences Berlin kkUniversity of Applied Sciences Wildau kkUniversity of Potsdam
36
BioTOPics 44 | May 2012 BioTOP-Report
IFHI
37
BioTOPics 44 | May 2012 BioTOP-Report
Biochrom AG Biochrom AG is a company dedicated to be a primary supplier of cell culture media and quality animal sera. The company manufactures and distributes the full range of products related to mammalian cell culturing technique: standard cell culture media, complete media tailored for particular cell types and cell lines, custom formulations, and animal sera, such as Fetal Bovine Serum (FBS). All sera are pre-
screened prior to acceptance; only those lots that meet strict quality control requirements are accepted for further processing and subsequent sale to customers. Serum products are tested for sterility, adventi tious viral agents, physico-chemical parameters, and biological performance. The manufacturing processes are de signed for the specific needs of customers engaged in biotechnological research, development, and biopharmaceutical production. Biochrom AG specializes in meeting customers‘ specifications and regulatory concerns, to facilitate the manufacture of custom media consistent with Good Manufacturing Practice (GMP). The media are produced in a strictly controlled environment; chemicals used conform, where applicable, to grade standards of European Pharmacopoeia and US Pharma copoeia. Biochrom AG produces lot sizes of sterile industrial buffers up to 4,000 litres, sterile media up to 2,000 litres, powder media up to 20,000 litres and customized sizes in smallest quantities.
Biochrom AG and TPP Techno Plastic Products AG (Switzerland) are exclusive partners for the sale of TPP products for cell culture and general laboratory equipment in Germany. Address Biochrom AG Leonorenstraße 2-6 12247 Berlin · Germany Phone +49 30 779 90 60 Fax +49 30 771 00 12 info@biochrom.de www.biochrom.de
caprotec bioanalytics GmbH caprotec bioanalytics GmbH has developed a ground-breaking, proprietary technology to reduce the complexity of protein mixtures in a targeted and directed manner. Founded in 2006 by scientist and entrepreneur Prof. Dr. Hubert Köster, founder of Sequenom Inc. and Biosyntech, caprotec raised since 2007 approx. 11 million Euro. Caprotec is operational in Berlin Adlershof since September of 2008 and currently has 26 employees.
caprotec’s Capture Compound Mass Spectrometry (CCMS) Technology is based on multifunctional small molecules that are used to target, capture, and isolate proteins based on their function. The company is commercializing the CCMS technology as kits for research applications and in the form of interactive research collaborations with the pharmaceutical, biotech and agrobiochemical industry. In collaborations for drug development caprotec is using small molecule drugs or drug candidates to establish a
CCMS profiles small molecule interactions with the proteome
Selectivity function (drug/molecule of choice)
Photoreactivity function Sorting function (isolates drug/molecule‘s specific binding partners)
38
(captures protein binding partners)
k Target ID k Toxicity ID k Pathway analysis
profile of proteins that interact specifically with the small molecule drug in a mixture of human proteins. The profile can be used to elucidate the mode of action of drugs and drug candidates and also to discover off-target proteins that potentially could cause adverse side effects in humans, e.g. liver toxicity. Address caprotec bioanalytics GmbH Volmerstraße 5 · 12489 Berlin · Germany Contact caprotec bioanalytics GmbH Phone +49 30 63 92 3990 info@caprotec.com · www.caprotec.com
BioTOPics 44 | May 2012 BioTOP-Report
BioTeZ Berlin-Buch GmbH BioTeZ is focused on biotechnological products and services for life science research, pharmaceutical industry and diagnostics. In many business fields BioTeZ has own technologies with outstanding properties, e.g., in the sphere of immunoaffinity columns, HRPlabeling, sundry streptavidin coatings and the development of enzyme immunoassays. On the basis of many years' experience the powerful diagnostic tool recoveryELISA® was created for monitoring therapies with biologics.
Business fields at a glance: Immunoaffinity chromatography kk Production of customized IAC kk Coupling of different ligands, e.g. antibodies against mycotoxins Premium oligonucleotid synthesis kk DNA / RNA incl. modifications
Contact BioTeZ Berlin-Buch GmbH Robert-Rössle-Straße 10 13125 Berlin · Germany Phone +49 30 94892130 Fax +49 30 9494509 info@biotez.de www.biotez.de
Streptavidin coating kk Microplates and other surfaces and materials kk Polystrept R for high binding capacity, excellent for lateral flow assays ELISA development and services kk inclusive conjugate development, labeling, purification etc. Companion Diagnostics kk recoveryELISA® – a new diagnostic method to predict and to measure interaction between therapeutic antibodies or biologics and their target molecules.
Epigenomics AG Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon® 2.0, is a second generation blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A.
With clinical studies indicating a majority of colorectal cancers are detected with the test added to the convenience of a simple blood draw, Epi proColon® is expected to improve compliance for colorectal cancer screening and save lives through early detection of disease. Laboratory test services based on this technology are available in the U.S.A. and Canada by our partnering laboratories Quest, ARUP and Warnex.
For further information please visit www.epigenomics.com Address Epigenomics AG Kleine Praesidentenstraße 1 10178 Berlin · Germany Phone +49 30 243450 Fax +49 30 24345555 contact@epigenomics.com www.epigenomics.com
Epigenomics’ product portfolio further includes Epi proLung®, a confirmatory test aiding in the diagnosis of lung cancer that is marketed in Europe, and additional products in development for colorectal, lung and prostate cancer. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Berlin, Germany, and Seattle, WA, U.S.A.
39
BioTOPics 44 | May 2012 BioTOP-Report
Metanomics Health GmbH kk Wide metabolite coverage via combination of unbiased and targeted platforms kk Unique tox mode of action prediction through MetaMap®Tox database kk Excellence in systems correlation analysis of complex gene function relationships
Metanomics Health – a BASF Group company – applies comprehensive Metabolite Profiling (metabolomics) with biomedical data interpretation. Metabolite Profiling is defined as the parallel analysis of multiple endogenous and xenobiotic metabolites in biological systems. The core expertise of Metanomics Health resides in discovery and validation of biomarkers. Technologies kk Metabolite profiling platform with more than 75 GC-MS and LC-MS/MS instruments
Major R&D-Topics In cooperation with academic institutes and clinical experts Metanomics Health is running a large-scale diagnostic biomarker program. Areas include metabolic syndrome, heart failure, prostate cancer and multiple sclerosis to mention a few.
cation, efficacy and safety markers) kk Companion diagnostic development kk Cell culture & bioprocess optimization Address Metanomics Health GmbH Tegeler Weg 33 10589 Berlin · Germany Contact Dr. Tim Bölke · Managing Director Phone +49 30 34807 400 Fax +49 30 34807 401 company.info@metanomics-health.de www.metanomics-health.de
Market Segments Metanomics Health provides its services to pharmaceutical, diagnostics and nutrition companies. Technology applications include: kk Mechanism of action studies kk Mechanism of toxicity studies kkTranslational and clinical biomarker development (e.g. PK/PD, patient stratifi-
Alacris Theranostics GmbH Alacris Theranostics GmbH, operative since September 2011, is specialised in developing new approaches in personalised medicine for cancer patient diagnosis, treatment and drug stratification. Alacris has built up a next-generation sequencing center for the analysis of clinical samples and applies a systems biology approach for patient and drug
Unlocking The Power Of Individualised Medicine
40
stratification using the ModCellTM software which is exclusively licensed to Alacris. This approach has been originally developed in the department of Prof. Lehrach at the Max Planck Institute for Molecular Genetics. Based on genome and transcriptome information and including kinetic pathway information, mutation and drug databases it is providing a “Virtual Patient” model. This ”Virtual Patient” can predict the effects of chemotherapeutic treatment and optimised combinatory treatment for personalised medicine approaches. ModCellTM also facilitates biomarker discovery and "Virtual Clinical Trials" for patient and drug stratification. Alacris' work provides the opportunity for: kk finding targeted personalised treatment for the patient saving negative side effects kk reducing health costs for non-necessary kk treatment kk optimising stratification of drug treatment
kk providing more rapid approval of drugs in targeted non-randomised trials kk recovering "fallen angel" drugs for the pharmaceutical industry kk reducing animal testing via virtual trials Address Alacris Theranostics GmbH Fabeckstraße 60-62 14195 Berlin · Germany info@alacris.de www.alacris.de
BioTOPics 44 | May 2012 BioTOP-Report
LGC Genomics LGC Genomics (www.lgcgenomics.com) is the genomics division of the international science-based LGC Group. LGC Genomics has recently merged with KBioscience, a UKbased technology company providing its own range of SNP genotyping chemistry and novel instrumentation to the life science research and quality control communities. The combined company now provides a full range of high quality genomics products, services and solutions including sample preparation (primarily, nucleic acid extraction), nucleic acid sequencing, genotyping and biobanking. LGC Genomics has laboratories in the UK, Germany and North America along with sales and support staff in over 15 locations in Europe, America and the Far East. The portfolio includes: kk Genotyping services, assays and reagents kk Sanger and next generation sequencing services on Roche 454 & Illumina HiSeq 2000 platforms
kk DNA and RNA extraction products and services kk DNA/RNA biobanking including storage, retrieval and analysis services kk Reagents and consumables for molecular biology kk Pharmacogenetics and diagnostic services kk Laboratory instrumentation including plate sealers, liquid handling robots, high-throughput PCR thermal cyclers, plate readers and a suite of laboratory automation instruments Address LGC Genomics GmbH Ostendstrasse 25 · TGS Haus 8 12459 Berlin · Germany Phone +49 30 53042200 service@lgcgenomics.com www.lgcgenomics.com
co.don AG co.don® AG is a public biopharmaceutical company, founded in November 1993, since 2001 listed on Frankfurt stock exchange. co.don® AG manufactures cell-based tissue engineering therapeutics of the highest purity and to the highest quality standards. Its products represent a revolutionary process in the biological replacement of damaged articular cartilage, invertebral disc and bone by building up strictly autologous tissue without the involvement of any external carrier materials or additives. The application of the products may be minimally invasive or arthroscopic and so surgery and rehabilitation times significantly reduced for doctor and patient. Because no external materials are used, the risks of rejection, inflammation and infection are very slight.
co.don® AG is certified in accordance with DIN EN ISO 9001:2008. Furthermore, production, quality control and quality assurance have been certified in accordance with European Guidelines for Good Manufacturing Practice (EU-GMP) since 1997. In 1997 co.don® AG was the first biopharmaceutical company in Europe to be granted a permit for the manufacture of autologous chondrocyte and osteoblast transplants under section 13 of the German Drugs Law (AMG). co.don® AG‘s technological, production and regulatory expertise makes the company a first mover in the market for biological cartilage and bone replacement and a provider of highly effective, safe treatment options between pain therapy and endoprothetics.
Address co.don AG Warthestraße21 14513 Teltow · Germany Contact Matthias Meißner, M.A. Head Corporate Communications/IR/PR Phone +49 3328 4346 0 Fax +49 3328 4346 43 info@codon.de · www.codon.de
41
BioTOPics 44 | May 2012 BioTOP-Report Bioeconomy
Bioeconomy
Towards the Age of the Bioeconomy Bioeconomy stands for a sustainable and resource-saving “green” economy which uses biological resources more extensively than in the past and becomes increasingly independent of fossil raw materials. This is vital because population growth, limited resources and global warming require urgent action to master the global challenges of the future. Biotechnology is essential to the development of the bioeconomy.
One approach is the industrial use of non-food materials which do not compete with food production. These are either renewable raw materials which are not used in the food sector (e.g. lignocellulosis, the structural matrix of ligneous plants) or biogenous waste and residual materials. Valuable substances for the pharmaceuticals, food and cosmetics industries can be obtained from these raw materials. In the German Capital Region, the potential of microalgae, for example, is being investigated at the research institute IGV GmbH, while other research in the region focuses on the extraction of vitamins and further secondary substances from sallow thorn leaves for natural cosmetics.
Biopolymers and biobased synthetic materials form a key application field for the industrial use of biomass, i.e. the conversion of biomass into building blocks for the chemical industry. In the cooperation project LIGNOS (Aevotis GmbH, Fraunhofer Institute for Applied Polymer Research (IAP) and the University of Potsdam), enzyme systems are being optimised for the extraction of different lignocelluloses, from which biopolymers are obtained which are then processed in moulded products, fibres or fleece materials. The Leibniz Institute for Agricultural Engineering (ATB) in Potsdam-Bornim is a partner of the EU demonstration project BREAD4PLA, in which lactic acid is produced from waste bread. After being polymerised into poly-lactic acid (PLA), the material can be used to produce packaging foils for bread. To foster more intense interaction between the existing capabilities in the field of biopolymers and the plastics processing industry, BioTOP Berlin-Brandenburg will organise an innovation forum in 2012 in cooperation with Kunststoffverbund Berlin Brandenburg e. V., BASF Schwarzheide GmbH and the Fraunhofer IAP. Berlin and Brandenburg have recognised the strategic and economic importance of the bioeconomy for their regions. A “Potential Analysis of the Regional Bioeconomy in Berlin and Brandenburg” was performed in late 2011 to investigate the existing capabilities and identify the innovation potentials in the field of renewable raw materials . The analysis showed that Berlin-Brandenburg has the potential to play a decisive role in the development of the bioeconomy in Germany and Europe. A short version of the analysis can be downloaded on www.biotop.de/Biooekonomie
Figure : Regional players in the field of industrial biomass use. The following sectors are involved: agriculture and forestry, plant breeding/horticulture, wood/cellulose/paper, chemicals (from biological raw materials), cosmetics, pharmaceuticals (from biological raw materials), new materials/bio-polymers, textiles, environmental technology and waste disposal/recycling. The size of the circles corresponds to the number of players in the respective area. (Source: genius gmbh – science & communication.)
42
Tradition and Innovation based in Berlin
Research is carried out here Our research focuses on: analytical chemistry, pharmaceutical development and clinical research. Our findings lead to innovative and proven quality compounds. In this way, we improve quality of life for many people. Here we produce ... The main focus of our product portfolio is medication for pain and diabetes therapy as well as for the treatment of disease relating to the cardiac and circulatory system or the thyroid gland. Patients have placed their trust in our medicines for over 100 years. From here we apply our know how on the market ... Especially in the eastern European markets; there we have over 31 representative offices. We supply patients worldwide within the Italian Menarini Group network. BERLIN-CHEMIE, a company in the Menarini Group, stands for tradition and innovation from Berlin.
For more information: BERLIN-CHEMIE AG 路 Glienicker Weg 125 路 12489 Berlin Phone: +49 30 6707-0 路 www.berlin-chemie.de
BioTOPics 44 | May 2012 BioTOP-Report
Global Business
The Role of Berlin-Brandenburg in the European Context Internationalisation was the main watchword for the Bioregion Berlin-Brandenburg in 2011. The reason is not hard to recognise: the region’s biotechnology companies earn the majority of their income abroad, and that share is rising! Companies in the industry need to look beyond national boundaries – and that applies even for very small ones. Especially they, however, often find it hard to implement an international strategy without customised external support.
Internationalisation and the challenges it presents were addressed at an early stage by both European and regional policies. At the European level, the new research funding programme Horizon 2020, which is to replace the old FP7, is of prime importance. The European Commission is not only committed to promoting the increased integration of research-intensive SMEs in European funding programmes, but regards that as essential. The details of the programme are currently being defined. Two things are already clear:
At the regional level, the increasing importance of internationalisation was also an important theme at the 4th Innovation Summit of Berlin and Brandenburg in August 2011. Here, Brandenburg’s Minister for Economic and European Affairs, Ralf Christoffers, launched a passionate appeal to the summit participants to seize the opportunities Europe provides and make use of the potential they offer.
Berlin meets Brussels 1. Horizon 2020 will incorporate and harmonise all EU research funding activities, have a total funding volume of 80 billion Euros and devote a large share of those funds to the support of innovative SMEs. 2. Berlin and Brandenburg are currently positioning themselves to ensure that their interests will be secured by H2020 and be prepared to benefit from the programme when it enters into operation.
44
This appeal is reflected in the theme of this year’s ‘Dialogforum’, a joint annual event of the states of Berlin and Brandenburg with the European Commission which was first held in 2007. Under the title “Improving Health for the Ageing Society” entrepreneurs from Berlin-Brandenburg in the fields of molecular diagnostics, medical engineering and regenerative medicine will engage in discussion with high-ranking representatives from European in-
BioTOPics 44 | May 2012 Global Business BioTOP-Report
stitutions and other life science regions in Brussels on 30 May 2012. The aim of the event is, on the one hand, to present innovative project proposals in the life sciences and receive direct feedback from the Commission‘s experts and programme directors. At the same time, the Commission is to receive first-hand reports about the experience of the companies represented with EU institutions and their funding instruments. This also provides companies with an opportunity to present their own input for the design of future funding programmes like Horizon 2020 and secure good positions on the starting line as funding candidates.
partnering especially for diagnostics companies with a regional conference was successfully made with the Euromediag International Convention (EIC) in summer 2011. With 127 participants from seven European countries, and 237 B-2-B meetings, the event made a promising start. The sequel will take place in June 2012 at the 4th Berlin-Brandenburg Technology Forum on In-vitro Diagnostics and Bioanalysis, which is being co-organised by the region’s Enterprise Europe Network, setting a positive signal for Berlin-Brandenburg and Europe.
The event is truly European in character due to the participation of many European SMEs and regional representatives from Denmark, France, the United Kingdom, Belgium and Sweden with whom Berlin-Brandenburg has networked intensively for many years and already cooperated in a range of projects. The dinner reception at the "Dialogforum" presents an exclusive opportunity for direct exchange with these European partners and with experts and politicians from Berlin-Brandenburg and the European Union.
A success story from Berlin-Brandenburg: The Trilateral Event 2011 As in the years before, scientists from France, Britain and Germany met in the French Embassy in Berlin in September 2011 for one and a half days of expert exchanges on the theme of „Innovative Health-Promoting Food“. Dr. Stéphane Roy Scientific Attaché French Embassy in Germany
European networks – Old friends, new formats Active cooperation in the networks of Europe’s BioRegions has played a central role in the internationalisation efforts in our region. BioTOP Berlin-Brandenburg is a founding member of the networks Council of European Bioregions (CEBR) and ScanBalt – a biotech network of the Baltic Sea states that celebrated its 10th anniversary in Heringsdorf on the island of Usedom in 2011. Through the Center for Molecular Diagnostics and Bioanalytics (ZMDB), the region is also a founding member of the still young European Diagnostic Clusters Alliance (EDCA), a network of leading European diagnostics clusters which currently represents more than 400 companies from the member regions. As the only German region in this network to date, Berlin-Brandenburg is regarded as one of the most high-performing regions in the alliance as regards both the number of companies and research facilities engaged in diagnostics development and the structures already established here (the ZMDB as a coordination platform and driver with a very clear focus). A main goal of this new European alliance is to provide targeted support to companies in the field of in-vitro diagnostics by means of customised support offers, activities and formats. The first attempt to combine European
The reinforcement of the partnership between France and Germany in the field of biomedical research is a key element of our strategy with BioTOP. The goal is to exchange the knowhow of different partners and develop new collaborations in cutting edge fields. This approach has proven highly successful for the last ten years.
Discussion focused on the latest research, developments and applications in the fields of nutrigenomics and functional food. Now running in its 7th year, the event is gaining recognition both as a high-level expert forum and as a partnering platform for scientific cooperation in Europe that is finding increasing interest among many target groups throughout Europe.
45
BioTOPics 44 | May 2012 BioTOP-Report
Education
Knowledge-Based Leadership
Berlin is one of the world’s most interesting and attractive cities – especially for young people. Here and in the adjacent region, they find excellent living conditions and outstanding sites of learning at five universities, seven technical colleges and more than 60 private and public research facilities. Especially in the life sciences, Berlin and Brandenburg are leading centers of academic teaching and research. The new edition of the Germanlanguage student guide „Studienatlas des Netzwerks Gesundheitswirtschaft HealthCapital Berlin Brandenburg“ published in spring 2012 offers a comprehensive overview of the region’s study programmes in the health and life sciences. It can be downloaded at www.atlas-studium.de
In Berlin and Brandenburg, science and industry cooperate closely and with impressive success. Due to intense networking between academic institutions and the region‘s many companies in the biotechnology, medical engineering and pharmaceuticals sectors, students can directly apply their knowledge in practice, deepen it and demonstrate it in their exam theses on cuttingedge themes. And the region also offers graduates many exciting career opportunities both in established companies and young start-ups.
Max Delbrück Center (MDC) in Berlin, which forms part of the Helmholtz Association, 84 % of junior research group heads have arrived from a position abroad, and more than half of these come from the United States. The German Chancellor, Angela Merkel, was impressed by the MDC’s efforts in promoting junior scientists and by the successful development of Germany as a research location during a visit at the MDC on 13 September 2011. www.helmholtz.de www.mdc-berlin.de
To maintain and extend its position as one of the world’s leading life science locations, the German Capital Region devotes considerable effort to attracting, educating and keeping the best young brains here. These activities include a wide range of continuing education programmes in both academic and extramural facilities as well as attractive funding programmes, some of which we present to you below.
Independent and international: The Helmholtz Association supports junior scientists The junior scientist programme of the Helmholtz Association is unique in Germany and offers young researchers from Germany and abroad the opportunity to conduct independent research at an early stage. In this programme, young scientists receive grants of up to 250.000 Euros annually for a period of up to five years. With these funds, they can set up and direct their first own research group. And, in doing so, they benefit from the excellent infrastructures of the Helmholtz Centers and from being part of a distinguished international working environment. This programme has enhanced the attractiveness of the Helmholtz Centers for junior scientists from around the world. At the 46
German Chancellor Angela Merkel (center) at a roundtable discussion with junior researchers at the Max Delbrück Center for Molecular Medicine (MDC) with Prof. Dr. Walter Rosenthal, Chairman of the MDC Board of Directors, Prof. Dr. Matthias Selbach, cell biologist and head of a Helmholtz junior research group at the MDC, Nuria Cerdá-Esteban, a Spanish postgraduate at the MDC, and Prof. Dr. Jürgen Mlynek, President of the Helmholtz Association. (Photo: David Ausserhofer/Copyright: MDC)
BioTOPics 44 | May 2012 Education BioTOP-Report
Interdisciplinary and with a strong focus on practical application: 25 years of biotechnology at Beuth University of Applied Sciences The Biotechnology Programme at Beuth University of Applied Sciences in Berlin, which is celebrating its 25th anniversary this year, is characterised by a high level of interdisciplinary cooperation and a strong focus on practical application on the interface between academic teaching, research and industry. Bachelor and Master students of biotechnology are trained here in biochemistry, bio-process engineering, microbiology as well as cell and molecular biology. After graduating they work in different industries and a range of fields in research, development, production or sales. Since Beuth University of Applied Sciences is participating actively in the future use of the Tegel Airport site, Campus Wedding and Tegel will gain additional space for modern teaching using the best facilities and equipment, including state-of-the-art laboratories.
Lifelong learning: BB LIFE seminars for entrepreneurs and service providers BB LIFE is designed for SMEs in the sectors pharmaceuticals, biotechnology, medical products/medical engineering and in vitrodiagnostics.
www.beuth-hochschule.de In Berlin and Brandenburg, biotechnology is also taught at Technische Universität Berlin (TU) and at Lausitz University of Applied Sciences in Cottbus. Prof. Dr. Steffen Prowe Director of Study Course Biotechnology at Beuth University of Applied Sciences Berlin
Our students from Germany and abroad are always fascinated by Berlin as a site of higher education. Student life is less expensive here than in other major cities, and the German capital offers a uniquely broad range of culture and leisure activities. Berlin’s closely networked biotechnology scene enables students to discover the many career options in the region’s biotechnology companies and institutions during their practical training phases. In addition, they benefit from the extensive industry experience and contacts of their professors and visiting lecturers from many institutions in Berlin and Brandenburg.
The seminars provide extensive information about the conditions and recommended procedures for the development, testing, manufacturing, approval and marketing of products and for the provision of services for these product groups. In addition to some “classics”, new themes are continuously researched based on the information needs of participants to ensure that all current developments in the regulatory field are addressed optimally. In the seminars, participants heard talks from more than 250 speakers to date, the majority of whom work in regional companies and research establishments.
An early start into the world of science To kindle enthusiasm for the life sciences among young people and foster their interest in scientific work at an early stage, Berlin-Brandenburg offers many initiatives which address school students in the region. They include the SchülerBIONNALE organised by BioTOP which attracts up to 1000 pupils every year. In lectures and at the booths of companies, educational facilities and universities, they can form a vivid impression of professional work and career prospects in the life sciences. Another very successful initiative is Call-a-Scientist which is organised by the Biotechnologieverbund Berlin-Brandenburg (bbb). More than 80 47
BioTOPics 44 | May 2012 BioTOP-Report Education
acclaimed scientists, professors and entrepreneurs are available here on request for lecturing in schools to report on the fascination of research, new research findings and the working practices and environment in universities and companies.
No other German region has as many laboratories for school pupils in such a compact area as Berlin-Brandenburg. In addition, many companies and institutions also provide information on themes in science and technology and hence also on the life sciences. The school student laboratories of the region’s research facilities and universities have established the network Schülerlabornetzwerk GenaU which provides information about all the information services on offer on its web page at www.genau-bb.de.
Information for everyone Other information sources for the general public in research facilities and universities are listed on the web page Berliner WissensWerte (www.berliner-wissenswerte.de) established and maintained by TSB Technologiestiftung Berlin. Users can view the wide range of information available according to themes, target groups and dates to receive inspiration for an excursion into the world of science.
Berliner WissensWerte wissen, wann und wo Wissenschaft passiert. Für alle Interessierten, Neugierigen, Vorschüler, Schüler, Lehrkräfte, Wissensdurstigen und Schlaumeier. Von der Langen Nacht der Wissenschaften bis zu den Tagen der Forschung. Die interessantesten und spannendsten Veranstaltungen, Vorträge, Labortermine, Führungen, Projekte, Programme, Ausstellungen, Experimente, Ferienangebote, Mitmachkurse, Workshops aus Naturwissenschaft und Technik in der Region.
Alles auf einen Klick: www.berliner-wissenswerte.de
den
nnen
pa CHHMA EN NAC IMENT ER EXP Mit s
Dieses Vorhaben der TSB Technologiestiftung Berlin wird aus Mitteln der Investitionsbank Berlin gefördert, kofinanziert von der Europäischen Union.
48
12049_AZ_BerlinerWissenswerte_105x195_HF.indd 1
19.04.12 11:44
BioTOPics 44 | May 2012 BioTOP-Report
Addresses
Networks 50 Biotech Parks 51 Other Parks 51 IP Asset Management 51 Universities and Research Centers 51 Banks and VCs 52 Supporting Organisations 53 Pharmaceutical Companies 53 Contract Manufacturers 55 Contract Research Organisations 55 Biotech Companies 56
F端r Unternehmen auf Wachstumskurs Wir st辰rken Ihr Eigenkapital. Wer in Brandenburg technologieorientierte Unternehmen gr端nden oder Wachstumschancen nutzen will, den unterst端tzen wir mit Eigenkapital und eigenkapitalnahen Finanzierungen. Bisher haben wir mit 150 Millionen Euro mehr als 120 Unternehmen auf ihrem Wachstumskurs begleitet. Wir sind Teil Ihres Erfolgs. Nehmen Sie Kontakt mit uns auf.
www.ilb.de
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Networks BioHyTec – Verein für Bioanalytik und Biohybrid-Technologien e. V.
BioHyTec is the biohybrid technology network in the life sciences cluster of Berlin-Bran- biohytec.de denburg. This new field of technology is the interface between biosensor development and microsystems technology. Biohybrid systems open up new applications in pharmaceutical research, clinical diagnostics, food analysis and genetic engineering.
BioResponseNetzwerk
BioResponse is an interdisciplinary research and development organisation with members bioresponse.de from Brandenburg, Berlin and Saxony. It focuses on the development and marketing of multiplex assays for diagnostic antibody identification based on the proprietary BioResponse technology, which is comprised of fully automated image analysis of fluorescenceencoded microparticles and labelled cell structures.
DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg
DiagnostikNet-BB is the Berlin-Brandenburg network for in vitro-diagnostics. Members diagnostiknet-bb.de include biotech companies as well research institutes and clinics. Main objectives of the network are: Development of system solutions, optimizing compatibility, close cooperation with leading clinicians and joint marketing.
GABI – Genomanalyse im Biologischen System Pflanze
GABI stands for Genome Analysis of the Plant Biological System and is an associative proj- gabi.de ect supported by the German Federal Ministry of Education, Research and Technology (BMBF) as well as a number private enterprise companies. These companies are grouped under the Business Platform promoting Plant Genome Research GABI e. V. (WPG). A Patent and Licence Agency associated with GABI (GVS) has the task of commercialising and protecting research results by means of licence rights.
Glykostrukturfabrik
The Network Glycobiotechnology Berlin-Brandenburg brings together scientists with many glykostrukturfabrik.de different areas of competence in studying and utilizing complex carbohydrates. The aim is product-oriented development of the region’s wide range of glycobiological technologies, building a complete glycobiotechnological process chain and to establish the region as a center of competence in the field of glycobiotechnology.
Health Capital Berlin-Brandenburg
In order to develop the scientific and economic position of the region, the governments healthcapital.de of the states of Berlin and Brandenburg have put the master plan “Healthregion Berlin Brandenburg” into effect. Its key to a continued success is a continued close interplay between research, development and education7vocational training with production, application and supply. All of these activities are integrated and coordinated through the Network “Gesundheitswirtschaft Berlin Brandenburg” under the brand of “HealthCapital”.
Network for Drug Discovery & Development (NetDDD)
The Network for Drug Discovery & Development Berlin-Brandenburg was launched in 2007 fmp-berlin.info/ as an open interdisciplinary initiative with the aim to accelerate the transfer of clinical technology-transfer/netddd relevant findings into innovative drugs and therapeutic concepts. The network was cofounded by the Leibniz-Institut für Molekulare Pharmakologie (FMP) and BioTOP BerlinBrandenburg. Next to offering support to research groups working on early drug discovery projects the NetDDD focuses on networking activities and professional training in the field of early drug development.
Netzwerk Nutrigenomik BerlinBrandenburg
Nutrigenomics is a highly innovative and fast-growing interdisciplinary field of research nutrigenomik.de linking genome research, plant biotechnology and molecular nutritional research and offering new applications for medicine and nutrition. Nutrigenomics aims at providing an understanding for how nutrition affects the balance between health and disease. Network partners include local universities and research institutes, private enterprises, public-sector organizations and various collaborative project groups.
Regenerative Medicine Initiative Berlin-Brandenburg
The mission of the RMIB is to promote the Berlin-Brandenburg region as a center of ex- rmib.de cellence for Regenerative Medicine particularly for cell-based medical biotechnology. The RMIB promotes networking in the field and supports the further development of clinical studies and education programs. The initiative fosters the collaboration between universities, research institutes, companies (including SMEs) and organizations in the field of science and technology.
RiNA -Netzwerk RNA-Technologien
The RNA-Network provides ongoing support and funding for the development of RNA tech- rna-network.com nologies with the goal to commercialize the results. One main focus is the improvement and application of the RNA interference technology. Further projects develop RNA aptamers, cell-free protein biosynthesis systems and analyse the structure and function of RNA molecules. The RiNA RNA-Network encourages co-operation and information exchange between academy and industry.
Zentrum für Molekulare Diagnostik und Bioanalytik
50
The Centre for Molecular Diagnostics and Bioanalytics (ZMDB) is a virtual centre operated zmdb.de under the auspices of the Fraunhofer Institute for Biomedical Technology and the Charité – Universitätsmedizin Berlin in close cooperation with the region’s company networks. The aim is to bring together regional expertise in basic research, technology development, clinical research and industrial cooperation initiatives to set up joint projects that will speed up the development of in vitro-diagnostics “Made in Berlin-Brandenburg”.
BioTOPics 44 | May 2012 Addresses BioTOP-Report
Biotech Parks berlinbiotechpark
berlinbiotechpark is located on a 86,000 m² site in the very heart of Berlin, currently berlinbiotechpark.de offering a total of approx. 57,000 m² of office, laboratory and production space, with a building potential for another 45,000 m² of rental area. Offering flexible growth potential, production-orientated media equipment and comprehensive industrial-specific services and infrastructure, berlinbiotechpark is particularly attractive for growing internationally orientated technology companies.
Biotech Campus Potsdam
Just a few minutes away from Potsdam’s central railway station in the direction of Caputh, biotechcampus.de BIOTECH CAMPUS POTSDAM is located on the Hermannswerder peninsula in the river Havel. It is owned and operated by BIOTECH CAMPUS POTSDAM GmbH, a fully owned subsidiary of the Investment Bank of the State of Brandenburg.
Biotechnologiepark Luckenwalde
Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg International bio-luck.de Airport in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one of the most modern facilities of its kind in Germany. It is home to 38 companies with 500 employees from Germany, USA, UK, Korea, India, Italy and Russia.
Co:bios Technologiezentrum GmbH The co:bios Technology Center in Hennigsdorf offers affordable rental opportunities and a cobiosselected portfolio of services and advice to young start-ups as well as medium-sized com- technologiezentrum.de panies. Therefore Hennigsdorf is a center of excellence for life sciences, especially in the field of red biotechnology and medical technology. Campus Berlin-Buch bbb Management GmbH
Berlin-Buch is home to one of the largest biotechnology parks in Germany, with 26.000 bbb-berlin.de square meters of scalable lab and office space for start-ups and maturing companies. Situated to the northeast of the city, the campus is currently home to 49 companies, 35 of which are biotech companies; the rest provide support services.
Adlershof Zentren für Biotechnologie und Umwelt
Berlin Adlershof is one of the most successful high-tech locations in Germany with focus adlershof.de on Photonics and optical technologies, material and microsystems technology, information and media technology, biological, environmental and energy technology. There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m of lab and office space.
Other Parks Science Park Potsdam-Golm GO:IN Golm Innovationszentrum GmbH
Science Park Potsdam-Golm is one of the most innovative and promising locations in Bran- wissenschaftsparkdenburg. In the GO:IN facility, innovative companies will find an excellent working envi- potsdam.de ronment where they will benefit from the synergy effects of the location and the specific goin-potsdam.de equipment offered by its laboratories. The location provides a wide range of services and consulting, as well as integration into the existing regional networks.
Innovationspark Wuhlheide
Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg International bio-luck.de Airport in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one of the most modern facilities of its kind in Germany. It is home to 38 companies with 500 employees from Germany, USA, UK, Korea, India, Italy and Russia.
IP Asset Management Ascenion
Ascenion advises public life science research institutions, universities, hospitals, freelance ascenion.de inventors and companies in all aspects of intellectual property asset management.
ipal GmbH intellectual property asset management
ipal assesses and markets the inventions of Berlins university scientists and academics on ipal.de an exclusive basis and is financed by the Berlin universities as well as the Investment Bank Berlin (IBB). Cooperation agreements exist with Charité, RKI, PEI, BAM and other excellent research institutes.
ZukunftsAgentur Brandenburg GmbH Brainshell
Brainshell is an independent consulting agency specializing in intellectual property ser- brainshell.de vices for businesses.Brainshell manages and markets the patent portfolios of all colleges, universities, and research institutes in the State of Brandenburg.
Universities and Research Centers BAM Federal Institute for Materials Research and Testing
bam.de
Berlin-Brandenburg Center for Regenerative Therapies
b-crt.de
Berlin Institute of Technology
tu-berlin.de
51
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Universities and Research Centers BfR Federale Institute for Risk Assessment
bfr.bund.de
Brandenburg University of Technology
tu-cottbus.de
Charité - Universitätsmedizin Berlin
charite.de
Deutsches Rheuma-Forschungszentrum Berlin
drfz.de
Fraunhofer Institute for Applied Polymer Research (IAP)
iap.fhg.de
Fraunhofer Institute for Biomedical Engineering (IBMT)
ibmt.fraunhofer.de
Freie Universität Berlin
fu-berlin.de
German Heart Instiute Berlin
dhzb.de
German Institute of Human Nutrition (DIfE)
dife.de
Humboldt-Universität zu Berlin
hu-berlin.de
htw Berlin – University of Applied Sciences
htw-berlin.de
Institute of Polymer Research of the GKSS Research Centre
gkss.de
Institute for the Reproduction of Farm Animals Schönow Inc.
ifn-schoenow.de
Lausitz University of Applied Sciences
fh-lausitz.de
Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB)
atb-potsdam.de
Leibniz-Institut für innovative Mikroelektronik
ihp-microelectronics.com
Leibniz-Institut für Molekulare Pharmakologie (FMP)
fmp-berlin.de
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
mdc-berlin.de
Max Planck Institute for Infection Biology
mpiib-berlin.mpg.de
Max Planck Institute for Colloids and Interfaces
mpikg-golm.mpg.de
Max Planck Institute for Molecular Genetics
molgen.mpg.de
Max Planck Institute of Molecular Plant Physiology
mpimp-golm.mpg.de
Robert Koch Institute (RKI)
rki.de
University of Applied Sciences Berlin
beuthhochschule.de
University of Applied Sciences Wildau
th-wildau.de
University of Potsdam
uni-potsdam.de
Banks and VCs BC Brandenburg Capital GmbH
bc-capital.de
Berliner Sparkasse-Kompetenzzentrum Gründungen und Unternehmensnachfolge
lbb.de
Berliner Volksbank eG
berliner-volksbank.de
bmp Life Science AG
bmp.com
Business Angels Club Berlin e.V.
business-angels-berlin.de
CCM Columbus Capital Management
columbusco.com
Commerzbank AG
commerzbank.com
Creathor Venture
creathor.de
Demeter Partners
demeter-partners.com
Deutsche Bank AG
db.com
High-Tech Gründerfonds Management GmbH
high-tech-gruenderfonds.de
IBB Beteiligungsgesellschaft mbH
ibb-bet.de
Investitionsbank Berlin
ibb.de
52
BioTOPics 44 | May 2012 Addresses BioTOP-Report
Banks and VCs Investitionsbank des Landes Brandenburg
ilb.de
KfW-Mittelstandsbank
kfw-mittelstandsbank.de
Peppermint Venture Partners GmbH
peppermint-vp.de
Ventegis Capital AG
ventegis-capital.de
Supporting Organisations Berlin Partner GmbH
Support of international and domestic companies in all issues regarding locating to Berlin. berlin-partner.de
BioTOP Berlin-Brandenburg
BioTOP Berlin Brandenburg is the central contact and coordination office for all issues biotop.de concerning biotechnology in the German capital region.
Investitionsbank Berlin (IBB)
Company financing and consultation on subsidies and processing grant applications in ibb.de Berlin.
Investitionsbank des Landes Brandenburg
Company financing and consultation on subsidies and processing grant applications in ilb.de Brandenburg.
Landesamt f端r Gesundheit und Soziales Berlin (LAGeSo)
One Stop Agency for all licensing and approvals, for questions concerning biomedicine, berlin.lageso.de biotechnology and pharmaceuticals and for more general issues connected with health, disease control and public health in Berlin.
TCC Technologie Coaching Center
Specific Coaching offers for innovative high tech companies.
Technologie Stiftung Brandenburg
The technology Foundation Brandenburg is dedicated to the advancement of science and ts-bb.de research, especially in the field of innovative technologies.
TSB Technologiestiftung Berlin Gruppe
The TSB Technology Foundation Berlin Group is a public private partnership in the Ger- tsb-berlin.de man capital region to develop science and industry networks for technology transfer, joint projects, and regional innovation strategies.
TSB Innovationsagentur Berlin GmbH
The TSB Innovation agency supports small and medium-sized companies in the manage- tsb-berlin.de ment of innovation processes.
ZAB Zukunftsagentur Brandenburg
The Brandenburg Economic Development Board functions as a one-stop agency for all zab-brandenburg.de kinds of business support services.
ZAK Zentrale Anlauf- und Koordinie足rungsstelle Senats足 verwaltung f端r Wirtschaft, Arbeit und Frauen
Helps you find your way through the Berlin administration. Supports complex urban devel- berlin.de/sen/wirtschaft/zak opment policy and investment projects.
tcc-berlin.de
Pharmaceutical Companies Advance Pharma GmbH
Contract manufacturer of solid drugs.Galenic development and admissions, analytics and advance-pharma.eu microbiology, coating and granulation (organic and aqueous), compacting, packaging.
ALPHAMADE GmbH
Customized formulations as medications: parenteral feeding, intradialytic parenteral feed- www.alphamade.de ing, omega-3 fatty acids, cytostatics.
Bausch & Lomb Dr. Mann Pharma
Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing bausch-lomb.de life for consumers around the world. Core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products.
Bayer Pharma Aktiengesellschaft
Bayer Pharma is one of the ten largest specialty pharmaceutical companies in the world bayerscheringpharma.de and the company's goal is a leading market position in each of its specialist fields. With its distinctive expertise in research, the company develops new medicines and therapies which make an essential contribution toward improving patient's quality of life.
BERLIN-CHEMIE Aktiengesellschaft
BERLIN-CHEMIE is a German subsidiary of the MENARINI Group. The company, which was berlin-chemie.de formed in 1886 and is headquartered in Florence, was developed over the generations to become a global, owner-managed pharmaceutical company. Research is centred on the development of innovative drugs for the following areas: inflammatory diseases and pain, cardiovascular diseases, oncology, viral disease.
53
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Pharmaceutical Companies Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH
CPL S: Custom synthesis development of active pharmaceutical ingredients (API’s), Con- cpl-sachse.de tract manufacture of active pharmaceutical ingredients from laboratory to kiloscale, Pharmaceutical analysis.
CT Arzneimittel
CT Arzneimittel is a pharmaceuticals company that focuses on generics production. Pre- ct-arzneimittel.de scription medicines form the bulk of the product portfolio, which includes some 1,200 drugs with more than 200 different active agents that are used to treat the most common clinical syndromes.
Dr. Kade Pharmazeutische Fabrik GmbH
The company’s activities concentrate on the production and marketing of drugs in the kade.de fields of gynecology, proctology, pain relief/ rheumatism and urology. The potential of proven drugs is expanded systematically by galenic developments to produce innovative products.
Haupt Pharma AG
With&nbsp,nine production sites Haupt Pharma is one of the leading contract manu- haupt-pharma.de facturers for pharmaceutical products in&nbsp,the world&nbsp,today.&nbsp,About 2.000&nbsp,employees produce for an established clientele of more than 200 important international pharmaceutical companies, amongst which 15 of the international TOP 25.
Heyl chemisch pharmazeutische Fabrik GmbH & Co. KG
HEYL is an independent, entrepreneurial family business that has its headquarters in prob- heyl-berlin.com ably the liveliest German metropolis, Berlin, since its establishment in 1926. In cooperation with our international subsidiaries, the main focuses of our work are the Regulatory Affairs and marketing of medicines as well as the sale of active pharmaceutical ingredients (API's) and special chemicals.
Klosterfrau Berlin GmbH
For more than 175 years Klosterfrau has been developing, manufacturing and market- www.klosterfrau.de ing pharmaceutical products. The profile of traditional yet modern natural medicines has grown significantly in recent times. Based on the latest scientific discoveries combined with the development of new markets, the range is constantly being expanded with innovative products.
medphano Arzneimittel GmbH
medphano Arzneimittel in Rüdersdorf stands for proven and cost-effective pharmaceutical medphano.de preparations. Main products are analgesics/anti-rheumatics, antibiotics, dermatics, diuretics, drugs to stimulate blood circulation, drugs for treatment of gastro-intestinal disorders, vitamins, expectorants, lipid-lowering agents, ophthalmics, cosmetics, food supplements, diet foods and foods.
MUCOS Pharma GmbH & Co.KG
As a specialist in enzyme preparations Mucos supplies a steadily growing market with mucos.de specific and variably dosed enzyme combinations. The company leads the world market in oral enzymes for therapeutic purposes.
Nycomed Oranienburg GmbH
As the competence centre for the development, production and packaging of solid dosage nycomed.de formulations Nycomed Oranienburg plays an important part in the global Nycomed operations network. It supplies the global pharmaceutical markets in more than 100 countries, from Europe to the US and Japan. The products include corporate Nycomed products and contract manufacturing for third parties.&nbsp.
Pfizer Pharma GmbH
Pfizer is the world's largest research-based biomedical and pharmaceutical company.
Pharma Action
Pharma Action has extensive expertise in global pharmaceutical marketing and manufac- pharma-action.com turing since 1988 and offers cutting edge API solutions to the pharmaceutical industry in Europe and abroad.
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis is a leading global pharmaceutical company based in Paris and operating sanofi-aventis.de in over 100 countries. R&amp,D teams work on a global approach to patients, offering innovative therapeutic strategies in thrombosis, cardiovascular diseases, diabetes, vaccines, oncology, the central nervous system disorders and internal medicine.
Shire Deutschland GmbH
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that www.shire.de focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal diseases.
Spreewälder Arzneimittel GmbH
Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food sup- spreewaelder-arzneimittel.de plements, diet foods and cosmetics in liquid, semi-solid and solid administration forms.
Steiner & Co. Deutsche Arzneimittelgesellschaft mbH & Co. KG
Production and marketing of pharmacy and prescription drugs, particularly plant-based steinerarznei-berlin.de drugs (tranquillizers, rheumatism drugs, bile duct and gastro-intestinal as well as gynecological and urological drugs), analgesics and mineral preparations.
Steripharm Pharmazeutische Produkte GmbH & Co. KG
Production and marketing of folic acid products.
54
pfizer.de
steripharm.de
BioTOPics 44 | May 2012 Addresses BioTOP-Report
Contract Manufacturers Advance Pharma GmbH
Contract manufacturer of solid drugs.Galenic development and admissions, analytics and advance-pharma.eu microbiology, coating and granulation (organic and aqueous), compacting, packaging.
ALPHAMADE GmbH
Customized formulations as medications: parenteral feeding, intradialytic parenteral feed- alphamade.de ing, omega-3 fatty acids, cytostatics.
Ayanda
Ayanda is an innovative business partner and manufacturer of consumer ready pharmaceu- ayanda.com ticals and food supplements. In Pritzwalk, Brandenburg, the company has a pharmaceutical soft gel encapsulation plant.
Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH
CPL SACHSE offers: Custom synthesis development of active pharmaceutical ingredients cpl-sachse.de (API’s); Contract manufacture of active pharmaceutical ingredients from laboratory to kiloscale; Pharmaceutical analysis.
Haupt Pharma AG
With nine production sites Haupt Pharma is one of the leading contract manufacturers haupt-pharma.de for pharmaceutical products in the world today. About 2.000 employees produce for an established clientele of more than 200 important international pharmaceutical companies, amongst which 15 of the international TOP 25.
Pharma Action
Pharma Action has extensive expertise in global pharmaceutical marketing and manufac- Pharma-action.com turing since 1988 and offers cutting edge API solutions to the pharmaceutical industry in Europe and abroad.
Spreewälder Arzneimittel GmbH
Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food sup- spreewaelder-arzneimittel.de plements, diet foods and cosmetics in liquid, semi-solid and solid administration forms.
Contract Research Organisations analyze & realize ag
analyze & realize ag is a leading CRO and consulting firm, which primarily give complete analyze-realize.com advice and guidance to companies in the natural products sector.
Assign International GmbH
Assign International in Berlin is part of the Assign Group, a mid-sized full-service CRO with assigngroup.com six offices in five countries.Our expertise meets development requirements of pharmaceutical and biotechnological industries. We manage clinical trials from study set-up to final clinical report.Our services, among others, comprise Data Management and Biostatistics, integrated EDC-Systems, Pharmacovigilance, Protocol Writing, Laboratory Services and Quality Management.
BLS Preclinical Services
BLS Preclinical Services is a contract research organization (CRO) located in Berlin. BLS pro- bls-germany.com vides a range of highquality and integrated preclinical services in animal models. Through our highly skilled scientific partners we provide a “one-stop” service and tailored solution. We take the time to understand your business needs and provide comprehensive tailored solutions either in-house or in co-operation of our network. We are backed by a highly skilled scientific team with a wealth of experience in all disciplines of preclinical development.
Charité Research Organisation GmbH
Based in Berlin, the Charité Research Organisation (CRO) was founded in collaboration charite-research.org with Berlin‘s famous Charité University Hospital. This relationship fosters a level of cooperation with centers of clinical excellence that we think is unique in the industry. The CRO offers a whole new approach to the concept of partnering with centers of clinical excellence to facilitate access to patients, clinical expertise and specialist methodologies in support of early clinical development programs.
Cooperative Clinical Drug Research and Development (CCDRD) AG
CCDRD is an independent contract research organization (CRO). CCRDR is dedicated to of- ccdrdag.com fer creative and innoative full service from planning to market authorization to its customers in the pharmaceutical, biotechnological and medical device industry.
CSG Clinische Studien Gesellschaft mbH
Since its foundation in 1998, the CSG Clinische Studien Gesellschaft mbH has focussed on csg-germany.com aligning clinical research with public health demands, with special attention to facilitating access by physicians and patients to clinical studies.CSG cooperates closely with the largest research institute for public health in Germany, the IGES Institut.
Dr. Notghi Contract Research
Dr. Notghi Contract Research GmbH is a service provider for large, medium and small-sized notghi.com companies in the pharmaceutical, generics and biotechnology industries. We support and advise you in the conduct and management of national and international projects.
Klinische Forschung Berlin GbR
Klinische Forschung Berlin is a study centre that implements clinical studies from phases klinische-forschungIIA to IV for the pharmaceuticals industry. berlin.de
55
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Contract Research Organisations Klinische Forschung Gruppe Nord GmbH
The Klinische Forschung Gruppe Nord (Clinical Research Group North) is a network of in- kfgn.de dependent investigator institutes with five centres in Northern Germany, two of them in Berlin.The Klinische Forschung Gruppe Nord has carried out trials with up to 250 patients. Phase II and III studies are the core competence. The test centres have altogether 30 overnight accommodation places for phase I and IIa studies.
PAREXEL International GmbH
The German subsidiary of the US clinical research organization PAREXEL employs more parexel.com than 1,400 people in Berlin. In two units with a 160-bed capacity (incl. 8 sleep lab beds) and an annual enrollment of approximately 2,500 volunteers in Berlin, more than 75 clinical studies are performed each year.
Sacura GmbH
Sacura is a full-service contract research organization granting a high level of quality (FDA sacura-cro.com approved), flexible structures and qualified staff.
Biotech Companies 3B Pharmaceuticals GmbH
3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company based 3b-pharma.com in Berlin, Germany. The company is dedicated to the development of peptide-based pharmaceutical and diagnostic products. 3BP is pursuing projects in hemophilia and nuclear medicine.
8sens.biognostic GmbH
8sens.biognostic develops, produces and sells rapid tests (lateral-flow) and ELISAs for dif- biognostic.de ferent markets (human and veterinary diagnostics, food control). Our products are the QuickSens®-tests for h-FABP, TropI, CRP and hs-CRP and the Reader for quantification QuickSens®OMEGA. Development-on-demand, feasibility studies and production-on-demand are also offered.
ABiTEP GmbH
The ABiTEP GmbH is working in development and production of biotechnological products abitep.de for sustainable agriculture. The team of ABiTEP works for development of non GMO customer specific technologies in laboratory scale and scale up with modern equipment and Know how. Capacities for fermentation up to 5.000 L, down stream equipment as well as freeze drier with capacity of 90 L are available for services. A molecular biology lab is available for basic science.
Accelero Bioanalytics GmbH
Accelero® Bioanalytics GmbH is a biotech CRO focussing on GxP compliant bioanalytical accelero-bioanalytics.com ligand binding assays. The company supports PK and PD preclinical/ clinical drug development on microRNA, miRNA, siRNA, aptamers, plasmid APIs, antisense drugs, as well as peptide hormones, biosimilars, antibody therapeutics, or cell-based therapeutics (ATMP). The Applied Biosystems Viia7 real-time qPCR system with IVD label for human Dx operates in full compliance to Good Laboratory Practice (GLP).
Adrenomed AG
Development of biologics against severe sepsis.
Aevotis GmbH
The core competencies of aevotis lie in the targeted conversion of simple carbohydrate aevotis.com containing substrates (e.g. agricultural by-products, waste streams, inexpensive sugars) to high-value carbohydrate based products, their characterization, processing and testing. Marketable products include novel /optimized enzymes, expression systems,&nbsp, specialized biotransformation and down-stream processes, customized oligomers and polymers for food and non-food uses.
AFOSA GmbH
Development, production and marketing of diagnostics (ELISA kits), primarily for use in afosa.com veterinary medicine.
Aglycon Mycoton GmbH
Aglycon Mycoton GmbH is active in the research, development and application of bio- aglycon-mycoton.net polymers as well and their manufacture and the sales and marketing of products based on these.
AJ Innuscreen GmbH
The AJ Innuscreen GmbH is a young life science company working in the field of biotech- aj-innuscreen.de nology and boosts the life science unit of Analytik Jena AG. Innovative technologies and products are developed and produced for the isolation and purification of nucleic acids. Reagent systems for molecular biology, as well as technologies and products for molecular diagnostics, are also included in the product portfolio. The company is EN ISO 9001:2008 and EN ISO 13485:2003 + AC:2009 certified.
Alacris Theranostics GmbH
Alacris Theranostics GmbH is a company based in Berlin specialised in developing new alacris.de approaches in personalised medicine for cancer patient diagnosis, treatment and drug stratification. Alacris is applying a systems biology approach that has been developed in the Department of Prof. Lehrach at the Max Planck Institute for molecular Genetics and is exclusively licensed as ModCellTM to Alacris.
Alcat Europe GmbH
Alcat Europe GmbH is the daughter of the US company Cell Science Systems, the original alcat-europe.com developer of the Alcat test technology. The company is specialized to identify intolerant reactions of the leucocytes to foreign substances like foods, drugs or chemicals.
56
adrenomed.com
BioTOPics 44 | May 2012 Addresses BioTOP-Report
Biotech Companies ALRISE Biosystems GmbH
ALRISE is a drug delivery company that specializes in the nano- and micro-encapsulation of alrise.de active ingredients. Using its globally patented ImSus® technology, ALRISE are developing parenteral deposit pharmaceutical forms for proteins, peptides or small molecules. Customers are mainly large pharmaceutical companies who are developing improved administration forms for active ingredients whose patents are expiring together with ALRISE as part of their “Product Lifecycle Management”.
Amocol Bioprocedures Ltd.
Amocol Bioprocedures Ltd is a life science research & development and manufacturing amocol.com company headquartered in Germany. Our mission is to supply innovative affinity chromatography media products and protein purification tools for research scientists and clinical customers in public sector institutes and industry.
AnaKat Institut für Biotechnologie GmbH
AnaKat Institut für Biotechnologie GmbH has specialized on analytical determination of anakat.de pharmaceutical ingredients.
Analyticon Discovery GmbH
AnalytiCon is a biotechnology company focusing on the development of compound librar- ac-discovery.com ies consisting of natural product (NP) and synthetic small molecules. As the global market leader in NP small molecule screening compounds, AnalytiCon is the only company which is able to provide vast collections with completely disclosed structural information. As a pure compound provider the company is offering its products and services to the pharmac., chemical, biotech, cosmetical and nutraceutical industry.
Analytisches Zentrum Biopharm Berlin GmbH
Analytisches Zentrum Biopharm GmbH Berlin is a contract research organization providing analytischesservices on pharmaceutical analysis and bioanalysis for active compounds in the dosage zentrum-biopharm.de form, for the quantitative determination of analytes in a biological matrix and also the determination of physicochemical parameters of chemicals according to OECD guidelines. AZB carries out these services in compliance with GLP and GMP and has the GLP certificate.
AnaTox GmbH & Co. KG
The AnaTox GmbH & Co. KG deals with the development and optimization of analytical anatox.de methods and devices for HPLC and dissolution.
Anau Berlin-lab GmbH
Development and distribution of lab devices.
ANiMOX GmbH
Development of applications for the use of natural peptide / amino acid mixtures in chem- animox.de istry and biotechnology, f.i. as a scavenger material in formaldehyde bounded formulations, foaming or hydrophobic Tensid compounds or as a N-source in biotechnological fermentation processes, distribution of a technology for the production of such basic materials from raw and residual materials.
Aokin AG
Aokin AG is a Berlin biotechnology company that is specialized in the development and aokin.com commercialization of innovative analytical systems on the base of the rapid kinetic assay technology. The aokin systems are unique in their precision and operating speed. Areas of application are food and antibody analytics as well as clinical diagnostics. We also offer laboratory services in the area of food analytics, Pharmacoanalytics and chemical synthesis.
AptaRes AG
AptaRes is a developer and manufacturer of aptamers as an alternative to antibodies. The aptares.de aptamers are isolated in vitro by using a proprietary technology. AptaRes is also developing aptamer-supported processes and analytical methods. It provides also consumables required for the aptamer applications. In collaboration with financial partners AptaRes supports with its enabeling technology entrepreneurs and the expansion of biotechnology companies.
ARGUS Umweltbiotechnologie GmbH
ARGUS is a medium-sized company. Since 1987 ARGUS works on the field of remediation argus-umwelt.de of contaminated groundwater, soil, waste water and waste air. ARGUS is able to elaborate a specific remediation program in each different pollution case considering economic aspects beside ecological aspects. All necessary treatment steps can be planned and carried out. The combination of microbiological steps with classic processes leads to a successful remediation of complex contamination.
ASCA GmbH Angewandte Synthesechemie Adlershof
ASCA is a partner for contract research in the field of medicinal chemistry. The synthesis asca-berlin.de and optimization of lead structures, the development of new active structures and their check on a laboratory scale are offered. We take a lot of care on working out the synthetic schemes, rapid preparations and exact analysis of the samples. All our results are carefully documented for our customers. Access to literature databases and in-house analytical facilities are available.
Astra Biotech GmbH
Astra Biotech GmbH offers high quality reagents, allergens, antibodies, recombinant pro- astrabiotech.de teins, and assays for the determination of hormones, allergies, tumour markers and infectious diseases. Quality is one of the key cornerstones on which Astra Biotech maintains its reputation and with which we strive to increase customer satisfaction and gain growing customer loyalty. We take great pride in our highest quality assays, which are all IVD compliant and therefore suitable for direct, accurate and reproducible diagnostic purposes, as well as for research.
eurolab24.com
57
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Biotech Companies ATLAS Biolabs GmbH
ATLAS Biolabs GmbH is a leading provider of microarray based genomic services such as atlas-biolabs.com genome wide gene expression and SNP analysis, CGH analysis and diagnostic services for registered doctors and hospitals, as well as for pharmaceutical, biotechnological and diagnostic enterprises.
Attomol GmbH Molekulare Diagnostika
The company’s aim is to develop, produce and distribute medical diagnostics for human attomol.de medicine in the field of molecular genetics, infectious and autoimmune diseases.
AudioCure Pharma GmbH
AudioCure is focus on the clinical development of drug candidates for neurodegenerative audiocure.de diseases with high unmet medical need.
AutoTissue GmbH
The company is engaged in the development, production and marketing of medical devices autotissue.de for cardiovascular surgeons. The products are specially made for the patients and have less side effects. The first certified product was a pulmonary heart valve (Matrix P) for the right ventricular outflow tract reconstruction (RVOT). The second product is also a heart valve which considerably shortens the operation time (Matrix P plus). Meanwhile a complete glutaraldehyde free valve is available called Matrix P plus N.
Bavarian Nordic GmbH
Bavarian Nordic is a leading international biopharmaceutical company developing, produc- bavarian-nordic.com ing and marketing innovative vaccines to prevent and treat infectious diseases and cancer.
Bbi-biotech GmbH
In the focus of the activities of bbi-biotech lie systems for the sterile sampling from bio- bbi-biotech.com reactors for all applications in the biotechnology, pharmaceutical, food, cosmetics and chemical industry. In addition, bbi-biotech develops components - in especially disposable ones - for the preparation of a new generation of fermentors and bioreactors and offers consulting and planning services for biotech projects, its implementation and services.
BEB BioEnergy Berlin GmbH
Planning, Design, Construction, Supervision and Implementation of Biogas/Hydropower bebgmbh.de plants, Preplanning, Feasibility Studies and Research activities in the field of renewable energies, Optimization of the process in existing biogas plants.
BG Berlin-Genetics GmbH
BG Berlin-Genetics GmbH is a new provider for genetic diagnostics and consulting in ge- bg-berlin-genetics.de netic diagnostics. We are a team of experienced human geneticists and have worked for many years in the field of human genetic science and human genetic diagnostics. Our aim is the development of innovative cooperation concepts, to connect classical patient-based medical care centers with modern technology-based service centers. In future, these cooperation forms will enable efficient, high quality, and patient-based genetic diagnostics.
Bioanalyt GmbH
Bioanalyt develops and distributes the worldwide first easy-to-use and portable test kits for bioanalyt.com the analysis of vitamins and micro nutrients. The iCheck-iEx test kits enable food producers, food authorities and NGOs to monitor their ongling food programms more efficiently and at low-cost. The company was founded in 2006 by Prof. Dr. F. J. Schweigert as a spin-off of the University of Potsdam. Read more on our website www.bioanalyt.com.
Bioassays GmbH
Service related to the development of medical in vitro-diagnostic products. Basic science to bioassay-online.de clinical development. Profiling of biomarkers in clinical trials.
Biochrom AG
Biochrom is Germany’s largest manufacturer of cell culture products (media, sera, and oth- biochrom.de ers) and sterile liquids. They are distributed to universities, industrial cell culture laboratories and industrial manufacturers. Service is of special significance for users of cell cultures. Special media developments and production optimizations are offered.
BIOCYC Gesellschaft für Biotechnologie und Recycling mbH & Co.KG
Production of bio-chemicals, peptides, in vitro-diagnostics, test-kits. Development of con- quartett.com sumer service for peptides and biochemicals.
BioGenes GmbH
BioGenes is a full service immunoassay and antibody (monoclonal and polyclonal) develop- biogenes.de ment company with outstanding problem solving capabilities specializing in challenging projects that are carried out by an exceptionally experienced and interdisciplinary team.
Bioline GmbH
Our mission is to provide customers with a range of products which are fast and easy to bioline.com use, guaranteed to work and developed by scientists who understand what our customers are trying to achieve so they can focus on their scientific goals. Bioline reagents are used by molecular biologists and other research scientists to perform test-assays and research in many fields from medical, biotechnology and marine biology.
BioMedion GmbH
IT-Service for all GxP-Regulatory Tasks Data- and Document Management, Long-Term-Ar- biomedion.com chiving and Digital Signature, SOP-Management, CAPA, Raw Data Management, Consulting for Validation of Computerized Systems according to GAMP4/5.
Biorefinery.de GmbH
Based on main precursors of plants, carbohydrates in kind of sugar, starch and cellulose, biorefinery.de and proteins, the biorefinery.de company has developed four complex product lines (Biorefinery systems) which leads to a great number of valuable products with the help of chemistry and biotechnology.
58
BioTOPics 44 | May 2012 Addresses BioTOP-Report
Biotech Companies BioRepro GmbH
BioRepro is the first pharmac. company, whose core competency is the breeding of leeches biorepro.de under controlled laboratory conditions for medical therapies. We concentrate on the establishment of GMP breeding procedures and will be able to provide leeches with standardized quality while equally allowing scalability to supply medical demand. Additionally, through the re-initiation of fundamental research, we will gain deeper understanding of further potential in medical and cosmetic treatment areas.
BioS Biotechnologie Schönow GmbH
Embryo transfer and associated biotechnologies in animals. Service, training and research bios-schoenow.de in this field.
BioSilta Europe GmbH
BioSilta is an international company that specializes in advanced tools for microbial cell biosilta.com cultivation, protein production, enzyme screening and food spoilage testing. The patented EnBase® technology resembles fed-batch mode and provides a cultivation environment with glucose-control, pH maintenance and inhibition of growth-limiting metabolites without the need for traditional mechanical pumps. EnBase® is provided in ready-to-use liquid or tablet products. BioSilta specializes in small-scale cultures and it?s products offer customer solutions from multi-well plates to small-scale bioreactors. Learn more about our products and applications at www.biosilta.com.
BIOSYNTAN Gesellschaft für bioorganische Synthese mbH
BIOSYNTAN offers the custom synthesis of standard peptides, the synthesis of modified biosyntan.de peptides (e.g. glyco- and phosphopeptides, dye labeled peptides) and hapten modifications for the conjugate synthesis. In cooperation with BIOGENES GmbH Berlin we offer poly- and monoclonal antibodies.
Biotech-Laboratorium für Environment BLE GmbH
Development of detection systems which are able, economically and rapidaly, to detect oil contaminations and industrial oil waste, in soil and in water and their biological depletion. The BLE GmbH is concerned with the biological degradation of oil contaminations and the development of a set of bio-preparations consisting of different bacterial strains which break down oil.
BIOTECON Diagnostics GmbH
BIOTECON Diagnostics has been well known as a qualified partner in the field of molecular bc-diagnostics.com and microbiology for the last 13 years. We focus on development, production and marketing of PCR-based rapid detection systems. BIOTECON Diagnostics offers solutions for the food and beverage industry as well as for producers of pharmaceuticals and cosmetics.
BioTeZ Berlin-Buch GmbH
Services (Custom DNA and RNA Oligonucleotide synthesis, Immuno affinity columns) - De- biotez.de velopment of Enzyme Immunoassays, e.g. for Therapeutic Antibodies- Bio Conjugates - Immobilization of Bio Molekules for better Signalling-R&D (Aptamer).
BIOWORX -BiotechnologielaborThomas Grimm
BIOWORX offers services in the fields of contract research for customer-specific Biotrans- bioworx.de formations, the screening, isolation and production of Biocatalysts from microorganisms and plants and the bioanalytic syntheses. Further organic compounds and metabolites will be synthesized with enzymes for customer in kg scale.
BiRDS Pharma GmbH
BiRDS Pharma GmbH, integrated into the BDD/CCDRD group, provides services in the field birdspharma.com of drug development to pharmaceutical and biotech companies, including management of drug development projects as well as consulting services. The company also pursues own drug development projects based on intellectual property generated within BDD/CCDRD group, with a focus on drug candidates derived from Atomic Substitution Technology (AST).
Botiss medical AG
Botiss biomaterials is a privately owned biotech company, headquartered in Berlin. botiss botiss.com is the leading German specialist for dental bone and tissue regeneration (BTR). We focus on the development of innovative regenerative materials and clinical marketing / distribution in over 50 countries world-wide. The botiss subsidiary Cell+Tissue Bank Austria is a leading European manufacturer of allogenic materials for hard tissue regeneration.
Breecon GmbH
The breecon GmbH is an innovative service company in life science with focus on green breecon.com biotechnology. The objectives of the company are consulting, application and mediation of biotechnological-analytical services as well as their development and marketing. The breecon GmbH offers his services to plant breeders and companies of the industrial biotechnology and supports the utilization of genetic diversity in the context of SMART breeding.
BST Bio Sensor Technology GmbH
BST develops and produces biosensors to provide high quality analysis at moderate prices. bst-biosensor.de In 1982 BST brought on the market the first multi-way biosensor based blood glucose analyzer in Europe and is since then market leader in Europe. Today BST sells more than 60.000 sensors a year. Since 2008 BST is besides biosensors also manufacturer of POCT and laboratory instruments.
59
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Biotech Companies Caprotec bioanalytics GmbH
Caprotecs Capture Compound Mass Spectrometry (CCMS) Technology allows to separate caprotec.com and identify proteins based on functionality. For many applications, CCMS is clearly superior to conventional methods - thus addressing an unmet need in the proteomics research community. The company develops caproKits for research applications in the life science area targeting the fields of protein kinases, signal transduction and epigenetics. Furthermore, the company is commercializing the CCMS technology through ImproMed projects with pharmaceutical and biotechnology companies. The focus on those collaborations is on investigating mechanisms of drug action (MoA), identification of on- and off-target proteins to understand potential adverse effects of drug candidates on a molecular level. This can be easily carried out in the lead optimization process, or even earlier to increase the probability of success later on in the clinics.
Capsulution Pharma AG
Capsulution Pharma AG develops innovative nano- and micron-sized capsules. The com- capsulution.com pany applies its worldwide-patented so-called LBL-Technology速. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules (500 nm to 50 袖m) can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer.
Cavira GmbH
Cavira is active in the field of infectious diseases and oncology. For the time being two cavira.de products are in preclinical stage with encouraging in vitro and in vivo data. One product is a derivate of a well known chemotherapeutic. The other one is combination therapy based on the amino acid depleting enzyme Histidinase with broad potential in both, oncology and infectious diseases. Research and development are conducted in cooperation with very well known universities or contract research organizations.
Celares GmbH
Specialist for Drug Delivery of peptides/proteins by using PEGylation. Modification of celares.com Biopharmaceuticals with polyethylene glycol in order to substantially improve pharmacological properties. Offers the unique CelaSYS-PEGylation technology, which is patented by celares. CelaSYS: non-dispersed, highly branched polyethylene glycol based reagents. Additionally celares offers customized PEGylation solutions as well as synthesis of customized PEG-reagents.
CellServe GmbH
CellServe is a service provider for research groups in regenerative medicine and fills an cellserve.de important gap in the conversion of applied treatment concepts from research into marketable products. Furthermore CellServe develops own innovative cell-based products for cardiology and uses novel cardiac derived cells ("From the Heart to the Heart") for the treatment of chronic heart failure.
CellTrend GmbH
Celltrend is certified according to ISO 9001, ISO 13485 and GMP Cell culture systems for celltrend.de research on active substances (bioassays, preclinical research, for quality control)Development and production of antibody-based detection systems (ELISA) Chemosensitivityassay for optimisation of chemotherapy (tumor patients).
Chemicell GmbH
Chemicell develops and produces magnetic, fluorescent and coloured nano- and micropar- chemicell.com ticles, reactive fluorescent dyes and special chromatography-materials for the separation or detection of cells, bacteria, viruses, proteins or DNA/RNA and new gene transfer systems.
Chipron GmbH
Chipron GmbH specializes in production and distribution of array based detection systems chipron.com for DNA/pathogens.
CHIRACON GmbH
chiracon is a qualified partner to develop chiral intermediates at a constant high qual- chiracon.de ity for innovative drugs regarding economic, environmentally acceptable and scaleable aspects. We offer support through expert knowledge and key technology to meet your increasing needs. Our core competence is chirality. In addition we have a broad variety of chiral building blocks as an inhouse raw material source for high-level API production and development.
CMZ-Assay GmbH
Marketing of diagnostic reagents for measuring concentrations of proteins, hormones and cmz-assay.com their isoforms, exclusively for research purposes.
Co.don AG
Co.don速 AG is one of the leading biopharmaceutical companies in the area of Regenera- codon.de tive Medicine/Tissue Engineering. Since 1997, co.don速 AG has developed, manufactured and distributed human Tissue engineering therapeutics for the regeneration of articular cartilage, bone and intervertebral discs.
CONGEN Biotechnologie GmbH
CONGEN is specialized in food testing by molecular analytics based on DNA and RNA congen.de detection. CONGEN has been a pioneer for over a decade in the development and application of food and feed analytics by real-time PCR. The methods are available as complete analytic kit as well as a Service. Our mission is to serve the food industry with an excellent service and with standardized and reliable test kits in order to realize highest possible food safety and food quality.
CREATOGEN Laboratories GmbH
Development of vaccines for application in veterinary and human applications.
60
BioTOPics 44 | May 2012 Addresses BioTOP-Report
Biotech Companies Cyano Biofuels GmbH
The company focuses on the biotechnological use of cyanobacteria, especially the devel- cyano-biofuels.com opment and optimization of cyanobacteria for the production of environmentally friendly biofuels and chemical feedstocks.
Cyano Biotech GmbH
Cyano Biotech identifies and characterizes natural products from cyanobacteria and opti- cyano-biotech.com mizes their pharmacological activities employing a biocombinatorial approach. The company conduct further development of identified lead structures till the preclinical phase.
Diaglobal GmbH
Development, production and distribution of in vitro-diagnostics for analytical purpose and diaglobal.de the distribution of medical products.
DIZG Deutsches Institut für Zellund Gewebeersatz gemeinnützige GmbH
DIZG German Institute for Cell and Tissue Replacement engages in cell and tissue preserva- dizg.de tion as well as in cell and tissue replacement, and provides tissue preparations of human origin to clinics, teaching and research organisations. Further service is culturing of skin cells (keratinozytes) for serious burns and other skin defects not healing well or affecting large areas. DIZG supplies cell cultures to help avoid experimentation with animals e.g. in the cosmetics industry.
Dr. Götz Verfahrenstechnik Biotechnik Umwelttechnik
Contract research and contract manufacturing using bacteria, yeasts and fungi.
Dr. Lerche KG
Innovative company engaged in development, production and marketing of specialized mi- lerche-biotec.com crocapsules for bio- and medical technology - Development and production of novel DNAPurification-Kits with proprietary technology - Production and marketing of microcapsules (LUMiTainer), microbeads and cell based sedimentation standards for blood analysis (SediVal ESR standards) - Encapsulation of cells - Contract analysis for characterization of microcapsules, porous membranes and hollow fibres.
Dr. Otto GmbH
Handling with research and development of ecological products its process of develop- dr-otto-gmbh.de ment also its production and marketing - Production and refinement of plantingredients - Operate an analytical laboratory of renewable resources and chem. Analysis.
Dr. Rölleke Labor für Genetische Analytik GmbH
Dr. Roelleke is specialized on the identification of microorganisms, particularly in the area dr-roelleke.de of food safety. Furthermore, Dr. Roelleke is authorized expert on paternity tests for courts and the private sector.
DSM Biopract GmbH
Service and Additives (enzymes, trace elements, microbes) for biogas and waste water dsmbiogas.com sludge treatmentEnzyme analysis in agriculture industryContract reserach feed additives.
Durakult GmbH
Durakult GmbH discovers and optimizes starter cultures and novel whole-cell catalysts for durakult.de customers in the food, chemical and renewable energy industries. durakult provides a new technology to explore microorganisms from natural untapped biodiversity for industrial applications. durakult stabilizes genetically manipulated cells which show weak growth or unstable metabolic properties and fits them to industrial purposes.
E.R.D.E.-AAK-Diagnostik GmbH
E.R.D.E.-AAK-Diagnostik GmbH is a laboratory that offers antibody testing for commercial aak-diagnostik.de purposes.
EMP Biotech GmbH
Production of fluorescent dyes and chemiluminescent reagents. Contract chemical syn- empbiotech.com thesis of small molecules. Contract labeling and purification of proteins, antibodies and oligonucleotides. Production of size-exclusion gels, columns and filter plates. Production of high quality reagents for DNA synthesis.
Epigenomics AG
Development and commercialization of innovative molecular diagnostic test products epigenomics.com based on DNA methylation for cancer screening and for cancer specialty applications.
Epinamics GmbH
Epinamics GmbH, a newly established Berlin based pharmaceutical research and develop- epinamics.com ment dedicated company, is owner of a proprietary film forming formulation technology platform, the ?Invisible Patch? system. The system is offering a broad basis for the development of formulations for treatment of dermatological diseases as well as for the development of transdermal systems.
Epiontis GmbH
Establishing methylation fingerprinting as Gold Standard for quality control in Regenera- epiontis.com tive Medicine and Immunomonitoring.
Epo Experimentelle Pharmakologie & Onkologie GmbH
The pharmaceutical and oncological testing of new drugs or treatment concepts for cancer epo-berlin.com is a specialized market segment. Using the equipment available, all experimental techniques can be carried out in first-rate quality. That means that EPO is an attractive partner for the drug development section of large pharmaceutical companies, for partners from the Biotech industry and for research institutions.
Eurovir Hygiene-Institut/Dr. Thraenhart
Laboratory service for testing the efficiency of products against viruses (virucides) and of eurovir.de processes for inactivating or eliminating viruses (virus safety).
drgoetz.de
61
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Biotech Companies EVESTRA GmbH
EVESTRA is a newly founded biotech company focusing on developing female health evestra.com products. The companies expertise resides with steroid chemistry and biology. EVESTRA’s product pipeline includes products for contraception, hormone replacement therapy, gynecological disorders and hormon dependent cancers.
F.A.T. Forschungsinstitut für Antioxidative Therapie GmbH
Measuring instruments and kits for evaluating the antioxidant properties and the degree antioxidantof oxidative damage in biological substrates. research.eu
Fermtec GmbH
Development of non-alcoholic beverages, beers and beer mix beverages, lactic acid fer- fermtecgmbh.de mentation, innovative foods and beverages and auxiliary substances for the food industry.
Ferropharm GmbH
Development of very small super para-magnetic nano particles as contrast agent for MRI.
FILT Lungen- und Thoraxdiagnostik GmbH
Development of innovative, non-invasive diagnostic methods in the area of respiratory filt.de diseases and allergies.
Formula GmbH
Galenical development of liquids and solid formulations Lyophilization Technolgy also formula-pharma.de apllicable for biochemical products Granulation, drying and coating using fluid bed dryingtechnology, tabletting Development and validation of analytical methods including UPLC Stability testing (ICH / GMP related to on going) Import of medicinal poducts from nonEU-countries, manufacturing, quality control (re-test) and release for market in accordance with §16 AMWHV for medicinal products and clinical supplies GMP-certificat / Manufacturing license in accordance with §13 AMG.
GA Generic Assays GmbH
Development, manufacturing and distributing of in vitro-tests, focussing on autoimmune genericassays.com diseases, hereditary and infections diseases.
Gene Analysis Service GmbH
Gene Analysis Service is specialized on genetic testing of a number of rare hereditary dis- gene-analysiseases and provides nucleic acid based molecular biological services like PCR and custom service.de DNA sequencing for healthcare providers and research institutes worldwide.
GenExpress Gesellschaft für Proteindesign GmbH
GenExpress is a flexible company providing services in molecular biology. For over a de- genexpress.de cade we have successfully worked for customers in clinical laboratories, research institutions and the industry. We offer cloning of PCR targets, preparation of synthetic genes, expression of proteins, evaluation of LightCycler® assays, furthermore production of internal controls and standards for Real Time PCR systems, also cloning, expression and purification of proteins.
GILUPI GmbH
GILUPI is a medical diagnostics company with an initial focus on the prenatal and cancer gilupi.com market. The company is developing an innovative new diagnostic product based on nanotechnology. Our goal is to catch specific cells, which can be found only in very low concentration in the blood. The first application for our new nanosensor device will be prenatal diagnoses of chromosomal aberration out of maternal blood. The second application will focus on the early diagnosis of cancer.
GlucoMetrix PVS GmbH
The GlucoMetrix AG focuses on the early detection and management of diabetes mellitus- glucometrix.de aftermath. At the foreground of research and development is the enhancing the quality of life of diabetics. In addition, the life science company develops some IT-based diagnostic procedures and medical devices as well as biopharmaceuticals and other highly effective products in order to raise the quality of life of diabetics sustainably.
Glycon Biochemicals GmbH
Production of carbohydrate components used for the synthesis of new pharmaceutical glycon.de compounds or diagnostics.
Glycotope GmbH
Glycotope is a leading company in glycomics and immunotherapeutics. It has developed glycotope.com novel therapeutic antibodies and unique platform technologies to optimize the glycosylation of new biological entities. Glycotope Biotechnology, with 25 years of experience in GMP-production, enables us to offer the entire process of biopharmaceutical development with a dedicated focus on our unrivalled expertise in protein glycosylation from the gene to production and fill & finish of clinical grade material.
Götz Protein Engineering
Offering a wide range of protein technology up to the final purified protein.
HealthTwiSt GmbH
HealthTwiSt is a service provider for “Genetic Contract Research” in the fields of Func- healthtwist.de tional Genomics, Epigenetics, Proteomics or Functional Food / Nutriceuticals. In particular, HealthTwiSt is offering access to extensively characterized human subjects and samples as well as prospective studies in twins, together with know-how in the analysis of complex genetic traits. Furthermore, database development, data management and statistical analyses for clinical projects are provided.
HF Biotec Berlin GmbH
Development, selling and operating of digestion plants using liquid substrates of industrial hf-biotec.com and agricultural provenience, Development and operating of combined plants to upgrade biogas into bio methane useable in public gas grids with parallel production and selling of high quality PCC, Development of innovative biotechnological processes and plants.
62
ferropharm.de
goetz-proteinengineering.de
BioTOPics 44 | May 2012 Addresses BioTOP-Report
Biotech Companies Human BioSciences GmbH
The biotech-company Human BioSciences Inc. is specialized in manufacturing and distribu- HumanBioSciences.de tion of modern collagen based wound and skin care products.
HUMAN GmbH
For over 35 years HUMAN has been serving the healthcare sector. HUMAN develops and human.de manufactures in Germany laboratory diagnostic products for the world market. HUMAN stands for quality and service in over 160 countries. In our new competence centre for autoimmune diagnostics, an expert team of highly specialized scientists and technicians develop and produce the IMTEC product line, a range of high-quality autoimmune diagnostic products. Further innovative products are to be launched soon!
Hybrotec GmbH
Hybrotec GmbH is specialized in the development of monoclonal antibodies and immuno- hybrotec.com assays (preferably homogenous assays) as customs service. Our main focus lies on antibodies binding low molecular weight substances (e.g. toxins, fluorophores, hormones) as well as antibodies against novel proteins.
Icon biotech
Icon biotech is an innovative biotechnology company, which uses the extraordinary charac- icon-biotech.com teristics of Ciliates for the development of bio-analytical and toxicological model systems.
Ifp Institut für Produktqualität GmbH
Ifp Institut für Produktqualität is a laboratory and competence centre for state-of-the-art produktqualitaet.com food, drinking water and pharmaceutical analysis. The accredited and GMP-certified company focuses on comprehensive services for the food and pharma industry. An additional core competence of ifp is the development and production of innovative diagnostics comprising the real-time PCR kits of the brand “mericon” (QIAGEN), vitamin tests in microtiter plate format, enzymatic microtiter plate kits for sugars/acids, and allergen tests in lateral flow and ELISA formats.
IGV Institut für Getreideverarbeitung GmbH
The range of services offered by the Biotechnology Division of the private research IGV igv-gmbh.de GmbH institute is based on 25 years of experience in R&amp,D for the cultivation of phototropic micro-organisms. Excellent, world-wide contacts to biomass producers, food producers, to the pharmaceutical and cosmetics and energy industry provide the fundament for innovative, market-oriented developments. In focus are development of photo bioreactor technology and active substances from algae.
IKDT Institut Kardiale Diagnostik und Therapie GmbH
IKDT was founded in August 2002 in Berlin-Steglitz and is one of the leading laboratories ikdt.de on Viral Infections of Heart Muscle Tissue and Dilatated Cardiomyopathy (DCM) in Germany. IKDT lab is performing a comprehensive molecular diagnostic examination of endomyocardial biopsies as one of a limited number of specialized cardiological labs worldwide. Its service enables physicians firstly to start an efficient, pathophysiologically based causal therapy.
ILBC GmbH
Research, consulting, production, trade & services in the areas biology, molecular biology mobiclup.de and protein chemistry - Expression and production of antimicrobial peptides.
ImaGenes GmbH
RZPD spin-off, today part of Source BioScience plc, a premier service center for genome imagenes-bio.de research and healthcare in Europe, provides one of the largest clone collections in the world via its clone search engine GenomeCube®. Certified Service Provider for illumina Next Generation Sequencing services and comprehensive microarray application on Affymetrix, Agilent, and NimbleGen platforms. ISO 9001:2008 certified.
In.vent DIAGNOSTICA GmbH
in.vent DIAGNOSTICA GMBH is a biomedical company. We are focused on the project- inventdiagnostica.de oriented provision, processing and distribution of biological raw material for development and production of diagnostics and control material. We are your reliable partner for the customised development of assays for medical in vitro-diagnostics.
inbion GmbH
inbion GmbH provides services to support research in the interface between university, inbion.de students and industry. For companies, we provide the benefit of outsourcing projects quickly and cost-efficiently to competent teams. Cooperation with research groups in the university is also facilitated, so that targeted knowledge transfer can take place here.
Innovative Optische Meßtechnik GmbH
Fluorescence Assay Solutions and Instrumentation (Microplate Readers).
Institut für Medizinische Gene tests for prenatal, predictive and tumor -diagnostics. Molekulardiagnostik (IMMD) GmbH
iom-berlin.de immd.de
Institut für Molekular- und Systemmedizin I.M.S.M. GmbH
Scientific-practical works in the area of System medicine with the purpose of the patenting of new treatment methods, e.g. to the treatment of diabetes. International cooperation in this area.
InterMune GmbH
InterMune is a biotechnology company focused on the research, development and com- intermune.de mercialization of innovative therapies in pulmonology and fibrotic diseases. In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.
63
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Biotech Companies InVivo Biotech Services GmbH
As a contract manufacturing company (CMO) Invivo offers a wide range of services: the invivo.de development and production of monoclonal antibodies and recombinant proteins for diagnostic and pre-clinical use (endotoxin-free antibodies and compliant documentation), cell line development and transient transfection. We are an ISO9001:2008 certified company.
InvivoContrast GmbH
InvivoContrast provides globally high quality MRI (Magnetic Resonance Imaging) contrast invivoContrast.com agents and professional support for preclinical imaging in academic and commercial institutions.
JPK Instruments AG
JPK Instruments AG is a world-leading manufacturer of nanoanalytic instruments - particu- jpk.com larly atomic force microscope (AFM) systems and optical tweezers - for a broad range of applications reaching from soft matter physics to nano-optics, from surface chemistry to cell and molecular biology. From its earliest days applying atomic force microscope (AFM) technology, JPK has recognized the opportunities provided by nanotechnology for transforming life sciences and soft matter research.
JPT Peptide Technologies GmbH
JPT is an ISO 9001:2008 certified provider of innovative peptide products and services and jpt.com a partner for research projects focusing on the development of novel immune therapeutics & diagnostics, profiling of various enzyme classes and proteomics. JPT has developed a portfolio of proprietary technologies and a series of unique products which support a worldwide customer base. Since 2011 all catalog products such as peptide microarrays & peptide pools are avalaible through an online shop.
Klinomed GmbH
Development of new technologies for manufacturing bio-active nano particles / develop- klinomed.de ment of therapeutic formulations based on nano particles.
KNAUER - Wissenschaftliche Gerätebau Dr. Ing. Herbert Knauer GmbH
KNAUER UHPLC and HPLC systems as well as columns are used in research and develop- knauer.net ment, quality control and production plant laboratories around the world. Customers are typically governmental and industrial organizations as well as universities. Fields of application are wide-ranging and include pharmaceutical and medical research, analysis of foodstuffs and cosmetics, as well as environmental analysis. With our biochromatography solutions we focus on high resolution separations.
L.U.M. Gesellschaft für Labor-, Umweltdiagnostik & Medizintechnik mbH
Analysis, diagnosis and sensor technology as well as stability, rheology and segregation lum-gmbh.de behavior of dispersions.
Labor Berlin - Charité Vivantes Services GmbH
The company is the service subsidiary of Europe’s largest hospital laboratory for clinical laborberlin.com pathology and offers complete solutions for any kind of testing for the ivd industry, CROs, the pharmaceutical industry, life science companies and research facilities. Labor Berlin performs&nbsp, over 20 million analyses in clinical pathology per year, it is the exclusive laboratory partner of Charité - Universitätsmedizin Berlin and the Vivantes Network for Health and provides the diagnostics for approximately 9.000 in-house patients a day and over 800.000 out-patients per year.
LAROVA Biochemie GmbH
Research, development and production of nucleotides, nucleosides, oligonucleotides in larova.com natural and modified forms.
LGC GmbH
Production of calibration substances for purity testing of drugs.
LGC Genomics GmbH
LGC Genomics is the division of LGC with specific expertise in high quality, cutting-edge lgcgenomics.com genomic and related services and products. LGC Genomics delivers:- Next generation sequencing services- DNA sequencing- Genomics services- Nucleic acid extraction servicesDNA extraction products. LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards (www.lgc.co.uk).
Limetec Biotechnologies GmbH
The core competence lies in the development of high-speed and high-quality proof systems limetec-biotechnologies.de for the detection of pathogens, as well as in the allelic discrimination of hereditary diseases. All products are marked with the CE-Certificate. The second area of expertise is the creation of communication networks which connect out-patient and hospital patient treatments, intensify data exchange and provide information to all health institutions, thus establishing partner relationships between them.
Lipidomix GmbH
LC/MS/MS based high trouput analytic of lipid mediators and metabolites. Analytical lipidomix.de/ method development, analytical support for LC/MS/MS in life science, food safety, forensic science.
MagForce AG
MagForce AG is a leading medical technology company focusing on nanomedicine in on- magforce.com cology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.
Marinpharm GmbH
Development and marketing of genetically altered cell lines on the basis of new fluores- marinpharm.com cence markers. Generation of stably transfected fluorescent cell lines.
64
mikromol.de
BioTOPics 44 | May 2012 Addresses BioTOP-Report
Biotech Companies Medical Enzymes AG
Medical Enzymes AG is a privately held innovative biopharmaceutical company with a fo- medical-enzymes.com cus on therapeutically useful enzymes. The company has developed a new product family based on amino acid depleting enzymes. This unique approach is highly effective against cancer - the major target market of Medical Enzymes AG.
MedInnovation GmbH
MedInnovation GmbH has developed a new method and a special ESR-analyser, which for medinnovation.de the first time allows a simple routine laboratory test for evaluation of functional characteristics of plasma proteins and further opens a reliable possibility for cancer diagnostic, named MMS-technology (mobility of molecular structure).
Medipan GmbH
Development, manufacturing and international distribution of radioactive (125J-IRMA) medipan.de and non-radioactive (Elisa) in vitro-diagnostic tests, covering the field of Autoimmunity, mainly in Thyroid and Diabetes Typ 1 and automated interpretation of cell-based immunofluorescence tests by the AKLIDES system.
MerLion Pharmaceuticals GmbH
The business purpose of the Company is the research, production, optimization and the merlionpharma.com development by way of pre-clinical as well as clinical trials of new molecules for the treatment of infectious diseases.
Merz Pharmaceuticals GmbH / Standort Potsdam
Merz is one of the leading research-based health care companies. Merz Pharmaceuticals merz.de has achieved a leading position in Alzheimer’s research with the world’s first drug for the treatment of moderate to severe Alzheimer’s disease. With high quality products from tetesept® and Merz Spezial®, Merz is making a key contribution to health and wellbeing.
Metabolomic Discoveries GmbH
Metabolomic Discoveries is an analytical service and research company. We provide mass metabolomic spectrometry based metabolite profiling and fingerprinting of biological material, as well discoveries.com as single compound measurements.
Metanomics GmbH
Metabolite Profiling for identification of gene function relationship in plants, metabolite metanomics.de biomarkers and metabolic networks.
Metanomics Health GmbH
Identification of metabolic biomarkers for pharmacology, toxicology, diagnostic and nutrition.
MetrioPharm AG
MetrioPharm AG develops innovative therapies for infectious diseases on the basis of new metriopharm.com and innovative medicines.
Mfd Diagnostics GmbH
The mfd Diagnostics GmbH (BT Luckenwalde) is a life science research and development mfd-diagnostics.com company for diagnostic and therapeutic application of innovative laser technologies. The main advantages of the developed technologies are the non-/minimally-invasive measurement methods, the non-artificial approach and the possibility of real-time measurement. Therefore, those are promising tools for the diagnosis and therapy monitoring in the neurological practice and in the perinatal surveillance.
MicroDiscovery GmbH
MicroDiscovery GmbH is a leading provider of high quality software for biomolecular re- microdiscovery.de search, innovative diagnostics and personalised medicine. The company is ISO 9001 certified and has a strong track record in creating software systems in accordance with relevant regulatory directives for the life science and IVD industry. Customised services ranging from biostatistical data analysis to bioinformatical design and support of complex research projects complete the product line of MicroDiscovery.
Microparticles GmbH
Development, manufacture, surface modification and characterization of mono-disperse microparticles.de polymer particles in the nano- and micrometer range. In addition to classic polystyrol and polyacrylate-based polymer particles, microparticles GmbH has launched new melamine resin particles on the market with exceptional chemical and physical qualities. The main areas of application are in particle measurement technology, medicine, biochemistry and microelectronics etc.
Minerva Biolabs GmbH
Minerva Biolabs develops and produces IVD kits for diagnosing pathogens and for con- minerva-biolabs.com tamination control, especially mycoplasma in cell cultures and biopharmaceutical products. Minerva Biolabs is also active in ensuring water quality with sensitive processes for detecting legionella. Our distributors ensure that our products are available worldwide, quickly and at a good price.
mivenion GmbH
mivenion is a life-science company founded in Berlin aiming on the development and mivenion.com commercialization of diagnostic and therapeutic products. The company is built on two innovative technologies: the fluorescence camera system Xiralite for diagnostic imaging of early rheumatoid arthritis and a proprietary bioactive polymer drug development platform. Xiralite is mivenion´s first product on the market.
MLB Mikrobiologisches Labor GmbH
Accredited test laboratory for drinking water, clean rooms, sterility, bioburdens, D-PL- mikroberlin.de 13398-01-00, EN 17025. Accreditation according to VDI 6022.
MolConcept GmbH
We offer computational drug design, rational drug design, and efficient simulation algo- molconcept.com rithms for molecular systems.
metanomics-health.de
65
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Biotech Companies Molnar-Institut für angewandte Chromatographie
Molnar-Institute, established in 1981, offers you a complete scientific and technical ser- molnar-institute.com vice for all problems concerning Quality by Design (QbD) for HPLC-methods. We develop for you the Design Space for your HPLC-separation and establish Critcal Quality Attributes (CQA’s). We offer detailed DryLab-courses and show you, how to develop robust methods in the Design Space and how to save time. We supply and implement the DryLab-software and train your coworkers. We assist you in automated method development processes and support you in the selection of proper instruments, their installation and use.
MOLOGEN AG
MOLOGEN AG is a biopharmaceutical company based in Berlin and specializes in the de- mologen.com velopment of novel DNA-based medicines against cancer and vaccines against infectious diseases. The proprietary platform technologies MIDGE® and dSLIM® build the foundation for all business activities. The company was founded 1998 and was one of the first biotechnology companies to go public.
MRI.TOOLS GmbH
MRI.TOOLS´s main focus is the development, sales and services of innovative hardware mritools.de and novel technology for magnetic resonance imaging (MRI), computed tomography (CT) and positron emission tomography (PET). Our product portfolio encompasses enabling radiofrequency (RF) coils tailored for a broad range of applications, devices designed for reliable cardiac gating of imaging plus accessories that will make your daily life more comfortable. MRI.TOOLS is also very proud to offer consulting services such as validation and certification of medical devices.
Nano Access Technologies Ltd.
The company addresses the combined access to key technologies such as life science and nano-access.com nanotechnology. As a first product, a low cost AFM for operation with so-called active cantilevers has been developed. Besides this, functionalized cantilevers for future biosensors are another focus of the company.
Nanolytics Gesellschaft für Kolloidanalytik mbH
We are a contract laboratory specializing in the physico-chemical characterization of phar- nanolytics.de maceutical proteins, biopolymers, nanoparticles and colloidal systems. Our core-competences are Analytical Ultracentrifugation, in combination with Static and Dynamic Light Scattering as well as spectroscopic (CD, fluorescence) and thermodynamic techniques (ITC, DSC).
Nanopartica GmbH
Nanopartica GmbH optimizes existing products of other companies, but are also develop- nanopartica.com ing new products and materials. In particular, companies in surface-, bio-, and medicaltechnology can benefit from nanopartica. By means of functionalized polymers, we can encapsulate guest molecules (drugs, dyes, vitamins), particles (gold, silver, platinum), or ions. This will indirectly change the guests properties and expands its scope.
nanoPET Pharma GmbH
As a technology and service provider to the biopharmaceutical industry nanoPET focuses nanopet-pharma.com on the R&D, production as well as marketing of innovative drug substances for diagnostic imaging based on novel nanoparticular materials. nanoPET offers consulting and contract research services, preclinical contrast agents (MRT, CT, US, NIR, PET) as catalog items and pursues the preclinical development of its patented core technology of inorganic nanoparticle PET tracers.
NovaBiotec® Dr. Fechter GmbH
Microbiological and chemical investigations, in particular of soil, water and air samples, novabiotec.de planning / inspection of sanitation, in particular analytics and sanitation support for mould and dry rot, incl. education in this field. Delivery of production auxilliaries and support for biogas plants with biological treatment processes incl. application, insulation and preservation of enzymes. Research, development and marketing of test kits for breweries and malthouses.
Novamol GmbH
Development and manufacture of human and veterinary food supplements and health- novamol.com enhancing products.
NOXXON Pharma AG
NOXXON Pharma is a biopharmaceutical company pioneering the development of a new noxxon.com class of proprietary therapeutics called Spiegelmers. Spiegelmers are the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics: Spiegelmer® NOX-E36, Spiegelmer® NOX-A12, Spiegelmer® NOX-H94. The Spiegelmer platform provides the Company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team.
NutriNeu GmbH
NutriNeu GmbH develops a new generation of pre and probiotics. First products are based on microorganisms that were isolated with our proprietary GlycoScreen technology (antibody directed isolation of microorganisms expressing specific carbohydrate structures). Besides developing own products, NutriNeu GmbH offers services in the fields of microbiology, process development and Glycoanalytic. NutriNeu GmbH also helps customers to investigate the probiotic properties of their microorganisms.
OakLabs GmbH
OakLabs provides the most flexible products and services for large scale custom SNP ge- oak-labs.com notyping on the market. OakLabs offers several formats for analysing a variable number of SNPs in any sequenced organism.
66
BioTOPics 44 | May 2012 Addresses BioTOP-Report
Biotech Companies OctreoPharm Sciences GmbH
OctreoPharm Sciences GmbH is a clinical development company focusing on diagnostic octreopharmsciences.com radiopharmaceuticals.
OpTricon Entwicklungsgesellschaft für optische Technologien mbH
OpTricon develops and produces mobile readers for quantitative analyzes of Immunoas- optricon.de says for Point-of-Care-diagnostics, especially Lateral Flow Assays (LFA). Additional business segments are components and Systems for signal transmission and sensors for lbioanalytics. opTricon develops the devices in partnership with the customers and works as OEM-suppliers and is certified by TÜV Rheinland according EN ISO 13485:2003+AC: 2007 and EN ISO 9001:2008.
ORGANOBALANCE GmbH
ORGANOBALANCE is a company specializing in microbial strain development and screen- organobalance.com ing. As a R&D contractor ORGANOBALANCE develops new biological products in the areas of nutrition, personal care and health care. The company draws on its own collection of microbial strains suitable for food applications and its OASSYS® bioassay systems. In the field of “metabolic engineering” ORGANOBALANCE exploits Saccharomyces cerevisiae yeast for synthesis of substances for the industrial and pharmaceutical industry.
ORGANOBALANCE Medical AG
ORGANOBALANCE Medical AG funds and promotes the research and development of nov- organobalance el therapies based on specific probiotic cultures, aiming to develop active substances and medical.com mechanisms for innovative medicinal products and medical devices, as well as offer new therapeutic concepts for hitherto inadequately treatable indications.
ovalehn GmbH
Production and application of specific recipes -containing IgY for diagnostics and oral, pas- ovalehn.de sive immune therapy.
Pentracor GmbH
In the case of cardiac infarction, C-reactive protein (CRP) results in an increase of the pri- pentracor.com mary damage. Based on a new prototype, the company Pentracor GmbH aims to develop an adsorber for therapeutic reduction of CRP, lead it to approval, establish its certified production and market the product after clinical validation.
Peptides&elephants GmbH
Custom synthesis of peptides and peptide libraries Development parallel Synthesis tech- peptides.de nologies Distributor of Peptide Synthesis Automation.
PharmaSol GmbH
Modification of ingredients or introduction of new metabolic pathways in plants with gene- pharmasol-berlin.de technology methods.
PlasmaChem GmbH
PlasmaChem GmbH is an innovative R&D and manufacturing company specializing in plasmachem.com nanomaterials, plasma- and ultra-thin film technologies. The company manufactures nanocoated medical implants (stents), nanomaterials, additives for metal plating (applied e.g. by Siemens AG), new additives to engine oils on the base of nanodiamonds and other industrial nanoproducts.
PolyAn, Gesellschaft zur Herstellung von Polymeren für spezielle Anwendungen und Analytik mbH
PolyAn is specialised in Molecular Surface Engineering (MSE). Using our surface modifica- poly-an.de tion expertise PolyAn optimises the performance of analytical systems by improving the signal-to-noise ratio as well as the reproducibility of consumables for multiplex diagnostics, LifeScience research and screening applications. PolyAn?s product portfolio includes functionalised microarray slides, microparticles for multiplex bead arrays and functionalised membranes for medical diagnostic applications.
Preclinics Gesellschaft für präklinische Forschung mbH
Preclinics is a commercial cooperation partner for preclinical research and development. preclinics.com As a competent, creative and experienced partner preclinics investigates pharmaceutical substances, therapeutic methods and proceedings as well as medical products during the preclinical phase. Additional we provide custom antibody production in llama, goat, sheep, rabbit and other species.
ProBioGen AG
ProBioGen is a Contract Development and Manufacturing Organization (CDMO) and Tech- probiogen.de nology Provider, with extensive expertise in cell line engineering, process development (upstream- and downstream process) and GMP manufacturing of biopharmaceuticals. Offering state-of-the-art contract development and manufacturing services as well as access to proprietary cell lines (AGE1.cell lines®) for the manufacturing of biopharmaceuticals and vaccines. The company possesses the manufacturing authorization from the competent authority and meets the quality standards required by the EMA and the FDA guidelines.
ProteaImmun GmbH
ProteaImmun is a specialized proteomic company providing purified human proteins, an- proteaimmun.net tibodies and ELISAs. Our proteins are designed for structural and functional studies of proteases screening and evaluation of protease inhibitors and modulators. Furthermore we develop highly sensitive ELISA kits and antibodies. Our Focus: MMPs, ADAMTs, HtrAs. ProteaImmun produces a unique range of recombinant proteases for medical and pharmaceutical research. The main focus is on human Matrix Metalloproteases (MMPs), ADAMTS and HtrA proteins which play an important role in neurodegenerative disease, ancer and arthritis. Customer Service: ProteaImmun provides activity analysis by zymography adapted for MMPs.
67
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Biotech Companies PROTEKUM - Umweltinstitut GmbH, We plan to eliminated fluid und solid waste products in a manner which is compatible with protekum.de Oranienburg environment protection. Our methodology is largely based on painstaking analysis. We use modern equipment and scientific methods. Protekum offers high-quality products and services in environmental analysis redevelopment. Proteome Factory AG
Biomarker & target discovery, validation, analysis of food and ingredients, absolute quan- proteomefactory.com tification of proteins and peptides, sequencing and characterization of proteins and antibodies (CDR), 2DE and LC-MS based proteomics studies, pharmacokinetics, pharmaco, immuno and membrane proteomics, protein identification, characterization of proteins and peptides (PTMs, e.g. phosphorylation, glycosilation), quality control, mass determination, N-terminal amino acid sequencing, silver staining kit etc.
Provitro GmbH
Provitro combines more than ten years of experiences in commercialisation of cell culture provitro.de technologies, Tissue Microarrays and immunohistochemical analyses with the scientific expertise of the Pathological Institute of the Charité, Berlin. Based on a quality management system according to ISO 9001:2008, we provide our customers not only with highquality products, CE marked in vitro-diagnostics and state-of-the-art services but also with individual solutions for their specific requests.
Rapidozym Gesellschaft für Laborhandel und DNA Diagnostika mbH
Expertise of cell biologists cell manufacturing and clean room technology specialists. Fo- rapidozym.de cuses on clinical stem cell product development portfolio are stroke, myocardial infarction and plastic surgery.
RENESA UG (haftungsbeschränkt)
Manufacturing and distribution of rapid tests, mainly for medical purposes (Point of Care renesa.de Testing).
Revotar Biopharmaceuticals AG
Revotar develops innovative small molecule drugs (SMD) for the treatment of chronic in- revotar.de flammatory disorders such as, chronic obstructive pulmonary disease (COPD), Acute Lung Injury (ALI/ARDS) and ischemia / reperfusion. With its drug candidate bimosiamose, Revotar has the worldwide most advanced pan-selectin-antagonist in clinical development in its product pipeline.
RiNA GmbH
RiNA has developed systems for cell-free protein biosynthesis based on pro- and eukary- rina-gmbh.eu otic cell lysates. A synthesis service is realised in RiNA’s own laboratories and complements the EasyXpress Kits (Qiagen). The purchase of Roche´s RTS-products enables RiNA now to be a key player in the field of cellfree biosynthesis with a large variety of products. Another research focus is the development of aptamers (DNA and RNA) for biosensors.
RIPAC-LABOR GmbH
RIPAC-LABOR offers high-quality diagnoses of bacterial infections, particularly in poultry, ripac-labor.de pigs and cattle, but also in other farm and domestic animals. The company uses pathogen differentiation to provide quick and effective methods for fighting pathogens. It performs resistance tests and epidemiological analyses and also focuses on producing herd-specific vaccines.
RNAx GmbH
RNAx specializes in RNA-Interference services. It offers functional validations of si- and RNAx.de shRNAs, target validation studies using automated high throughput approaches, as well as whole genome screens with automated assays.
RNL Europe GmbH
Manufacturing of stem cells from bone marrow and adipose tissue for therapeutic and pharmicell.eu plastic-aesthetical application. Manufacturing of adult stem cells for research (mesenchymal stem cells, endothelial precursor cells). Banking of stem cells.
Roboklon GmbH
Distribution, Marketing and Development of Products for Molecular Biological Research roboklon.de and Genetic Engineering.
ROVALAB GmbH
Our Master Mixes for QPCR, Standard-, Hot Start- and High Fidelity PCR as well as our rovalab.com high quality critical raw materials and reagents such as DNA Polymerases and dNTPs are designed to help you successfully and rapidly solve your scientific and manufacturing tasks.
Royal Biotech GmbH
Royal focuses on developing, manufacturing and marketing innovative kits, portable or royalbiotech.com micro-structured systems, and the next generation of diagnostic chips for near real-time environmental, food safety, disease and laboratory diagnostics.
Scienion AG
Scienion is a life science company in the markets of dispensing systems and microarray scienion.de technologies. The product portfolio comprises hardware, consumables and services. Scienion’s leading product is the sciFLEXARRAYER dispensing system, available in a product line of six size versions. The dispenser allows the aspiration of ultra low liquid volumes from different reservoirs and non-contact micro drop delivery in the picoliter to microliter range onto a variety of carriers.
Sepiatec GmbH
Production, development and sales of automated HPLC machines for high-throughput pu- sepiatec.com rification and fractioning of complex substance compounds.
68
BioTOPics 44 | May 2012 Addresses BioTOP-Report
Biotech Companies Seramun Diagnostica GmbH
Seramun offers peptide synthesis, purification and conjugation of proteins, production seramun.com of antibodies, customer research, in vitro-Diagnostics. We focus on the development and production of enzyme immunoassays for diagnosis of viral and bacterial infections and autoimmune diseases of the gastrointestinal tract, the development of multi-parameter assays as microtitre plate assays and as membrane immunoassays, as well as development of ready-to-use substrate solutions and for protein stabilizers.
SGS INSTITUT FRESENIUS Berlin GmbH & Co. KG
Analytical laboratory services and consulting for development, production and quality con- institut-fresenius.de trol of drugs.
SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin
Development, production and purification of monoclonal antibodies for use in diagnostics. sifin.de Development and production of blood grouping reagents, Serafol® bedside cards and test reagents for serotyping of Salmonellae, Shigellae, E. coli and Yersiniae. Development and production of culture media for microbiological diagnosis.
Signature Diagnostics AG
Signature Diagnostics is dedicated to the discovery, validation and commercial develop- signaturement of novel diagnostic products that predict outcome and drug response in patients with diagnostics.de colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and ovarian cancer. Signature believes that patient selection and stratification based on molecular gene signatures will soon become an important component of routine cancer treatment.
Silence Therapeutics AG
Silence Therapeutics AG is a leading RNAi therapeutics development company and offers a silencenovel, proprietary siRNA technology (AtuRNAi) and proprietary systemic delivery systems therapeutics.com for siRNA (AtuPLEX, DACC and DBTC). SILENCE pipeline consists of both partnered and internal programs of which 3 clinical phase II and 1 clinical phase I programs are partnered with Pfizer/Quark (2 ophthalmic indications) and Novartis/Quark (2 kidney indications). Silence?s internal lead compound Atu027 is currently in a Phase I clinical study for the treatment of solid tumours.
SINA Science Services GmbH
SINA is a modern company providing elaborate services in molecular biology and protein sina-science-services.de biochemistry. Together with our industrial partners and customers from research institutions we develop complex cloning and mutagenesis strategies including high-throughput applications. We offer cloning of genes, expression and purification of proteins, DNA and RNA isolation from numerous biological materials and the production of competent cells with high transformation efficiency.
SLM- Speziallabor für angewandte Mikrobiologie GmbH
Microbiological quality control for medical devices, pharmaceuticals, cosmetics, drinking speziallabor.com water, foodstuff, monitoring in clean rooms.
STRATEC Molecular GmbH
STRATEC Molecular GmbH is a globally active provider of innovative system solutions for invitek.de nucleic acid sample collection, stabilization, and both manual and automated purification from any sample type. Since 1992 the company is internationally respected for its outstanding and high performance technology platforms and offers a broad spectrum of superior products for molecular diagnostics, drug discovery and Life Science research.
Strix Diagnostics GmbH
Strix Diagnostics is a medical diagnostics company specializing in customized develop- strix-diagnostics.de ment of certified analytical systems for multiparameter in vitro-diagnostics.
Surflay Nanotec GmbH
Surflay Nanotec GmbH, a spin-off company from Capsulution NanoScience AG, is special- surflay.com ized on coating colloidal and planar materials with functional films. Key technology is the patented LbL-Technology® with polymers. Applications are in the fields of separation materials, pigment encapsulation, bio-sensing and diagnostic particles. In addition to customer tailored projects Surflay offers an unique range of products of tunable multifunctional nano-or microparticles and dye-labeled polymers.
Thanares GmbH
Development, use and marketing of analytical process for diagnostic and therapeutic pur- thanares.com poses. Future business activities: detection process for bioactive substances in bodily fluids, isolation, characterization and investigation of bioactive compounds from plants, in particular insoluble proteins or low concentrations of proteins, development of low cost genetic systems for over-expression and/or production of such proteins.
TheraKine BioDelivery GmbH
Development of antibody drug delivery systems and related tasks.
Thermo Fisher Scientific B·R·A·H·M·S GmbH
Thermo Scientific Biomarkers (B·R·A·H·M·S GmbH) explores, develops and produces new thermoscientific.com/ diagnostic test procedures to improve the diagnosis, and thereby the treatment, of life- brahms threatening illnesses. This takes place with over 470 employees, in the disease areas infectiology, cardiology and pneumology as well as thyroid, autoimmunity and cardiology on the basis of our own patented biomarkers. Since October 2009 B·R·A·H·M·S GmbH is part of Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science.
TIB MOLBIOL Syntheselabor GmbH
In 1990, TIB MOLBIOL became the first German manufacturer of oligonucleotides. In ad- tib-molbiol.com dition to designing and synthesizing primers and probes for Real-Time PCR assays, we develop and produce LightMix® Kits for Roche Diagnostics LightCycler® Instruments, covering applications in Clinical Chemistry, Pharmacogenetics, Pathogen Detection, as well as Cancer Research. TIB MOLBIOL is ISO 13485 and ISO 9001 certified.
therakine.com
69
BioTOPics 44 | May 2012 BioTOP-Report Addresses
Biotech Companies TransTissue Technologies GmbH
TransTissue has been a subsidiary of BioTissue Technologies, Freiburg since September transtissue.com 2001. With more than 15 years of experience in regenerative medicine, the scientists of TransTissue Technologies have developed second-generation autologous tissue replacements, e.g. cartilage and bone grafts. We are mainly concerned with inventions and the development of tissue engineering products for regenerative medicine. We offer a broad panel of services in the field of regenerative medicine.
UGA Biopharma GmbH
UGA Biopharma a private Research and Development company, focuses on Research, De- ugabiopharma.com/ velopment and Commercialization of Biopharmaceutical products under contract with de/index.html other Biopharmaceutical companies. UGA Biopharma conducts power of biosciences to develop high-tech, last generation of biomedicine, diagnostic kits, molecular biology items and also offers world class services in biotechnology area.
Umwelttechnik Dr. Bartetzko GmbH Feasibility studies, development, planning, construction and operation of biotechnological bartetzko.com plants for groundwater, process water and waste water purification. Accredited microbiological laboratory for the investigation of drinking water, groundwater, bath water, soils, food, anti-microbial active ingredients and sterility according to Ph.Eur, approved in accordance with BiostoffV and the German infection protection act (Infektionsschutzgesetz). VasoTissue Technologies GmbH
The company is active in the field of product development for advanced medical therapies. vasotissue.de For its first product - the endothelialised vascular graft (“VasoGraft”)- VasoTissue obtained a manufacturing license in 2008. Currently, VasoTissue´s focus is on conducting its first clinical trial.
Zellwerk GmbH
Zellwerk produces the proprietary Z® RP cell cultivation system, comprising rotating bed zellwerk.biz bioreactor, GMP Breeder, Control Unit, software. Bioreactors with 50-5000 ml volume, 0,2-2 m² seeding surface, different cell carriers, can be delivered. In this culturing system cells grow tissue-like, being embedded in self-generated extra-cellular matrix. The technology opens unique opportunities for the GMP-compliant expansion of stem cells and primary cells, manufacturing of cell-seeded implants as well as production of recombinant proteins. In addition, we have recently developed a new bioreactor for expansion of immune cells for cell therapy of leukemia and several types of cancer.
Zentrum für molekulare Onkologie GmbH
Innovative methods for diagnostic and therapy of tumor diseases - Molecular genetics (K- molekulareRAS, PCA3, Septin9, ...) - Chemoresistance assay for prediction of chemotherapy - Pathol- onkologie.eu ogy Development of new biomarkers and analytical services for studies.
Zytomed Systems GmbH
Zytomed Systems´ focus is the development, production and distribution of antibodies zytomed-systems.de and detection systems for immunohistochemical cancer diagnostics as well as reagents and kits for in-situ hybridisation.
70
Life Sciences. Living Research. Berlin. Brandenburg.
A vibrant network Berlin-Brandenburg is one of Europe’s leading locations for the Life Sciences. It is also an R&D capital that magnetically attracts the world’s top scientists. Here you’ll find attractive subsidy conditions, close linkages between business and science, the highest concentration of R&D in Europe, a dynamic startup scene and a multifaceted entrepreneurial environment made up of roughly 480 pharmaceutical, biotech and medical engineering companies. Come discover this one-of-a-kind landscape for scientists and entrepreneurs. www.biotop.de/business
BioTOP is a joint initiative of the state of Berlin and the state of Brandenburg under the umbrella of the TSB Innovationsagentur Berlin GmbH and takes part in the Cluster Management Health Capital. BioTOP is funded by the federal state of Berlin, the federal state of Brandenburg and the Investitionsbank Berlin, co-funded by the European Union (European Fund for Regional Development). Investing in your Future